Interim report
Page 1
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 1 30 October 2026 AstraZeneca results: 9M and Q3 2026 Continued strong commercial performance and 12 positive Phase III programme readouts in the year to date Revenue and EPS summary 9M 2026 % Change Q3 2026 % Change $m Actual CER1 $m Actual CER - Product Sales 43,962 7 5 15,066 5 5 - Alliance Revenue 2,806 33 32 1,107 36 36 Product Revenue 46,768 8 6 16,173 7 7 Collaboration Revenue 113 22 23 36 >3x >3x Total Revenue 46,881 8 7 16,209 7 7 Reported EPS ($) 5.62 10 11 2.02 23 26 Core2 EPS ($) 8.00 14 14 2.79 17 19 Key performance elements for 9M 2026 (Growth numbers at constant exchange rates) Total Revenue up 7%, with double-digit growth in Oncology, R&I and Rare Disease offsetting headwinds from Farxiga and Brilinta loss of exclusivity and volume- based procurement in China Core Operating profit and Core EPS increased 14% 47 approvals in major regions since Q4 2025 results, including first approvals for four new medicines (Etcamah, Baxfendy, Klygefa and Amlypave) First Phase III data for three NMEs (tozorakimab, efzimfotase alfa and sonesitatug vedotin) Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “In the first nine months we saw strong commercial momentum with total revenue up 7% and Core EPS up 14%, driven by our diverse therapy areas and global presence. We have had approvals for four new medicines and reported 12 positive Phase III programme readouts with a collective peak year revenue potential well in excess of ten billion dollars. Our rich series of upcoming readouts in 2027 has a potential of more than twenty billion dollars. With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, we are on track to deliver our 2030 ambition and to sustain growth through the next decade.” Guidance AstraZeneca reconfirms Total Revenue and Core EPS guidance3 for FY 2026 at CER, based on the average foreign exchange rates through 2025. Total Revenue is expected to increase by a mid-to-high single-digit percentage Core EPS is expected to increase by a low double-digit percentage The Core Tax rate is expected to be between 18-22% If foreign exchange rates for October 2026 to December 2026 were to remain at the average rates seen in September 2026, it is anticipated that Total Revenue in FY 2026 would benefit from a low single-digit percentage positive impact (unchanged) compared to the performance at CER, and Core EPS growth would be broadly similar (unchanged) to the growth at CER.
Page 2
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 2 Navigation tips The text in this contents page, and in the header at the top of every page, are hyperlinked – click one to navigate to a section or table. To return to the previous location after clicking a hyperlink, press + (Windows) or + (macOS) Example: - To see the definition of an acronym, click on ‘Glossary’ at the top right of the page. - After viewing the definition, press + or + to return to your previous location. Contents Results highlights ...................................................................................................................................................................................... 3 Revenue drivers ........................................................................................................................................................................................ 6 R&D progress .......................................................................................................................................................................................... 12 Sustainability .......................................................................................................................................................................................... 18 Operating and financial review............................................................................................................................................................... 19 Financial performance ............................................................................................................................................................................ 20 Interim financial statements .................................................................................................................................................................. 25 Notes to the Interim financial statements ............................................................................................................................................. 30 Glossary .................................................................................................................................................................................................. 41 Table 1: Milestones achieved since the prior results announcement ...................................................................................................... 3 Table 2: Key elements of financial performance: Q3 2026 ...................................................................................................................... 4 Table 3: Product Revenue (PR) by medicine ............................................................................................................................................. 6 Table 4: Collaboration Revenue ............................................................................................................................................................... 7 Table 5: Total Revenue by Therapy Area .................................................................................................................................................. 7 Table 6: Total Revenue by region ............................................................................................................................................................. 7 Table 7: Product Revenue by region ......................................................................................................................................................... 7 Table 8: Reported Profit and Loss........................................................................................................................................................... 20 Table 9: Reconciliation of Reported Profit before tax to EBITDA ........................................................................................................... 20 Table 10: Reconciliation of Reported to Core financial measures: 9M 2026 ......................................................................................... 20 Table 11: Reconciliation of Reported to Core financial measures: Q3 2026 .......................................................................................... 21 Table 12: Cash Flow summary: 9M 2026 ................................................................................................................................................ 22 Table 13: Net debt summary .................................................................................................................................................................. 22 Table 14: Obligor group summarised Statement of comprehensive income: 9M 2026 ......................................................................... 23 Table 15: Obligor group summarised Statement of financial position ................................................................................................... 23 Table 16: Currency sensitivities .............................................................................................................................................................. 24 Table 17: Condensed consolidated statement of comprehensive income: 9M 2026 ............................................................................ 25 Table 18: Condensed consolidated statement of comprehensive income: Q3 2026 ............................................................................. 26 Table 19: Condensed consolidated statement of financial position....................................................................................................... 27 Table 20: Condensed consolidated statement of changes in equity ...................................................................................................... 28 Table 21: Condensed consolidated statement of cash flows: 9M 2026 ................................................................................................. 29 Table 22: Net debt .................................................................................................................................................................................. 31 Table 23: Product Sales year-on-year analysis: 9M 2026 ....................................................................................................................... 36 Table 24: Product Sales year-on-year analysis: Q3 2026 ........................................................................................................................ 37 Table 25: Alliance Revenue: 9M 2026 .................................................................................................................................................... 38 Table 26: Collaboration Revenue: 9M 2026 ........................................................................................................................................... 38 Table 27: Other operating income and expense: 9M 2026 .................................................................................................................... 38
Page 3
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 3 Table 1: Milestones achieved since the prior results announcement Phase III and other registrational data readouts Medicine Trial Indication Event Enhertu DESTINY-Lung04 1L HER2m NSCLC Primary endpoint met Etcamah SERENA-4 1L HR+ HER2- advanced breast cancer Primary endpoint not met Imfinzi + tarlatamab DeLLphi-305 1L ES-SCLC (maintenance) Primary endpoint met Lynparza MONO-OLA1 1L BRCAwt ovarian cancer Dual primary endpoints met Tagrisso + Orpathys SAFFRON 2L+ EGFRm, MET-overexpressed and/or amplified NSCLC Primary endpoint met Tagrisso + Orpathys SANOVO 1L EGFRm, MET-overexpressed NSCLC Primary endpoint met volrustomig eVOLVE-Lung02 1L PD-L1 <50% mNSCLC Discontinued due to futility Tezspire CROSSING Eosinophilic esophagitis Co-primary endpoints met Ultomiris AWAKE Delayed Graft Function Discontinued due to lack of efficacy Regulatory approvals Medicine Trial Indication Region Datroway TROPION-Breast02 1L TNBC for patients where immunotherapy is not an option EU, JP, CN Enhertu DESTINY-Breast09 1L HER2+ mBC EU, JP, CN Enhertu DESTINY-Breast05 High-risk HER2+ early breast cancer (post-neoadjuvant) EU, CN Enhertu DESTINY-PanTumor02 HER2+ solid tumours CN Etcamah SERENA-6 ESR1m HR+ HER2- 1L advanced breast cancer US Imfinzi POTOMAC NMIBC JP Breztri KALOS / LOGOS Asthma EU, JP Klygefa (gefurulimab) PREVAIL Generalised myasthenia gravis JP Amlypave (anselamimab) CARES Kappa light chain amyloidosis JP Ultomiris I CAN IgAN US Ultomiris ALXN1210-PNH-323 PNH CN Regulatory submissions or acceptances* in major regions Medicine Trial Indication Region Calquence AMPLIFY 1L CLL (fixed duration) CN Imfinzi VOLGA MIBC not candidates for cisplatin US, EU, JP Truqap CAPItello-281 PTEN-deficient mHSPC CN tozorakimab OBERON / TITANIA / PROSPERO COPD US, JP Ultomiris I CAN IgAN CN Ultomiris ALXN1210-TMA-314 HSCT-TMA (paediatric) US efzimfotase alfa MULBERRY / CHESTNUT / HICKORY HPP US, EU, CN * US, EU and China regulatory entries in this table denote filing acceptance Other pipeline updates For recent trial starts and anticipated timings of key trial readouts, please refer to the Clinical Trials Appendix document in the financial results section of the AstraZeneca investor relations website: www.astrazeneca.com/investor-relations.html Results highlights
Page 4
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 4 Table 2: Key elements of financial performance: Q3 2026 For the quarter Reported Change Core Change ended 30 September $m Act CER $m Act CER Product Revenue 16,173 7 7 16,173 7 7 See Tables 3, 7, 23, 24 and 25 for further details of Product Revenue, Product Sales and Alliance Revenue Collaboration Revenue 36 >3x >3x 36 >3x >3x See Tables 4 and 26 for further details of Collaboration Revenue Total Revenue 16,209 7 7 16,209 7 7 See Tables 5 and 6 for Total Revenue by Therapy Area and by region Gross Margin (%) 82 - +1pp 82 - +1pp + Positive product mix effects − Pricing headwinds, including those driven by loss of exclusivity and VBP in China Variations in Gross Margin can be expected between periods due to various factors, including fluctuations in foreign exchange rates, product seasonality and Collaboration Revenue R&D expense 3,894 6 7 3,645 3 3 Core R&D: 22% of Total Revenue (23% for 9M 2026) + Increasing number of trials, and patients in those trials + Investments in transformative technologies + Addition of R&D projects from business development + Positive data readouts for high value pipeline opportunities that have ungated large late-stage trials Variations in the year-on-year change in R&D expenses can be expected between periods due to the phasing of trial starts and completions SG&A expense 5,108 - - 3,909 2 2 Core SG&A: 24% of Total Revenue (25% for 9M 2026) + Investment to support ongoing and future launches Variations in the year-on-year change in SG&A expenses can be expected between periods due to the phasing of product launches and other programmes Other operating income and expense4 277 >3x >3x 277 >2x >2x + Various partner milestones and royalties + Disposal of Zoryve interest Operating profit 4,387 22 26 5,855 17 20 + See commentary above on Gross Margin, R&D, SG&A Operating Margin (%) 27 +3pp +4pp 36 +3pp +4pp and Other operating income and expense Net finance expense 410 17 22 371 22 27 + Lower interest income on short-term deposits and higher interest expense on short-term borrowings + Higher discount unwind on lease liabilities, principally due to the new strategic R&D centre in Massachusetts, US − Reported Net finance expense benefitted from a lower discount unwind on contingent consideration liabilities Tax rate (%) 21 -1pp -1pp 21 - -1pp Variations in the tax rate can be expected between periods EPS ($) 2.02 23 26 2.79 17 19 + See commentary above For dollar values in this table, the unit of change is percent. For Gross Margin, Operating Margin and Tax rate, the unit of change is percentage points (pp). In the table above, R&D expense, SG&A expense and Net finance expense are displayed as positive numbers. The plus and minus symbols next to comments denote the directional impact of the item being discussed. For example, a plus symbol next to a comment about an R&D item indicates that the item increased R&D expenditure relative to the prior year period.
Page 5
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 5 Corporate and business development Summit Therapeutics In October AstraZeneca completed a $2bn equity investment in Summit Therapeutics Inc. (Summit). The investment gives AstraZeneca rights equivalent to approximately 12.0% of Summit Therapeutics’ outstanding common stock, or approximately 10.6% on a fully diluted basis. AstraZeneca and Summit entered into a clinical collaboration agreement to evaluate sonesitatug vedotin in combination with Summit’s PD-1/VEGF bispecific antibody ivonescimab. The two companies also entered into a clinical collaboration with Daiichi Sankyo to evaluate Datroway in combination with ivonescimab. AstraZeneca and Summit intend to enter into an additional agreement initiating a global development programme combining other AstraZeneca cancer medicines, including additional ADCs, with ivonescimab. Kendall Square R&D Centre In October, AstraZeneca formally opened its new global strategic R&D centre, in Kendall Square, Cambridge, Massachusetts. The state-of-the-art facility builds on the Company’s existing presence in Boston and Cambridge, Massachusetts and will be home to nearly 2,000 world- class researchers and scientists. Reshaping for Sustainable Growth AstraZeneca is in a catalyst rich period with more than 180 pipeline projects driving its next wave of growth and scientific innovation. To capitalise on this opportunity, the Company has initiated the Reshaping for Sustainable Growth (RSG) programme to create additional capacity to invest behind its industry- leading pipeline and transformative technologies. Over the next three years, the programme will redeploy resources and strengthen capabilities across AstraZeneca’s existing business and therapy areas. The RSG programme is expected to cost up to $2.0bn in one-time restructuring costs and deliver $1.5bn in annualised pre-tax run-rate benefits. The savings generated will continue to be reinvested back into the Company, principally in the pipeline. The Company anticipates activities to be essentially complete by the end of 2029. insitro In October, AstraZeneca entered into a strategic drug discovery collaboration and licensing agreement with insitro. Using advanced AI systems, the collaboration will identify novel drug targets and advance the design of new therapeutics for MASH and cardiomyopathies. Under the terms of the agreement, insitro will receive an upfront payment of $40m, and is also eligible for up to approximately $1.46bn in potential development and commercial milestones, plus potential single digit royalties based on global commercial sales. AstraZeneca will have exclusive worldwide rights to advance selected programmes identified under the collaboration. Dizal Pharmaceutical Co In August, AstraZeneca completed the license agreement with Dizal Pharmaceutical Co., Ltd for Zegfrovy, which is approved in the US and China for the 2nd-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. See Interim Financial Statements, Note 5, for further details. Sustainability highlights AstraZeneca ranked fifth on TIME Magazine’s 2026 World’s Best Companies list - its highest position to date and the top ranking among pharmaceutical companies - based on sustainability transparency, revenue growth, and employee satisfaction. Reporting calendar The Company intends to publish its FY and Q4 2026 results on 9 February 2027. Conference call A conference call and webcast for investors and analysts will begin today, 30 October 2026, at 14:30 UK time. Details can be accessed via astrazeneca.com. Notes 1. Constant exchange rates. The differences between Actual Change and CER Change are due to foreign exchange movements between periods in 2026 vs. 2025. CER financial measures are not accounted for according to generally accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported results. 2. Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges. A full reconciliation between Reported EPS and Core EPS is provided in Tables 10 and 11 in the Financial Performance section of this document. 3. The Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the Cautionary statements section regarding forward-looking statements at the end of this announcement. 4. Income from disposals of assets and businesses, where the Group does not retain a significant ongoing economic interest, is recorded in Other operating income and expense in the Group’s financial statements.
Page 6
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 6 Table 3: Product Revenue (PR) by medicine 9M 2026 % Change Q3 2026 % Change $m % Total Actual CER $m % Total Actual CER Tagrisso 5,862 13 10 8 2,087 13 12 12 Imfinzi 5,538 12 28 27 1,990 12 24 26 Calquence 3,009 6 18 16 1,065 7 16 16 Lynparza 2,421 5 1 (2) 811 5 (3) (3) Enhertu 2,688 6 36 33 969 6 36 35 Zoladex 967 2 9 5 336 2 13 10 Truqap 641 1 30 29 210 1 9 9 Imjudo 263 1 4 4 103 1 23 25 Datroway 176 - >4x >4x 78 - >3x >3x Etcamah 10 - n/m n/m 7 - n/m n/m Other Oncology 313 1 (3) (4) 109 1 2 3 Oncology PR 21,888 47 18 16 7,765 48 17 17 Farxiga 5,603 12 (12) (15) 1,605 10 (25) (25) Crestor 1,018 2 8 5 332 2 9 6 Lokelma 638 1 23 23 219 1 16 17 Seloken 519 1 11 6 182 1 14 9 Brilinta 261 1 (61) (62) 75 - (48) (50) Wainua 189 - 33 33 68 - 16 17 roxadustat 78 - (66) (68) 21 - (73) (74) Baxfendy 12 - n/m n/m 9 - n/m n/m Other CVRM 298 1 (29) (30) 92 1 (36) (34) Cardiovascular, Renal & Metabolism PR 8,616 18 (11) (15) 2,603 16 (19) (20) Symbicort 2,084 4 (4) (7) 666 4 (10) (11) Fasenra 1,655 4 14 13 602 4 13 14 Breztri 1,073 2 18 16 374 2 16 14 Tezspire 1,123 2 46 44 429 3 50 51 Saphnelo 615 1 27 27 235 1 31 32 Pulmicort 378 1 6 2 109 1 18 16 Airsupra 129 - 12 13 42 - (7) (4) Other R&I 211 - (9) (11) 61 - 3 1 Respiratory & Immunology PR 7,268 16 12 10 2,518 16 11 11 Beyfortus 427 1 (10) (10) 233 1 (1) (2) FluMist 172 - 30 29 146 1 20 20 Other ID 136 - (38) (41) 44 - (24) (25) Infectious Disease PR 735 2 (11) (12) 423 3 2 1 Ultomiris 4,016 9 16 16 1,432 9 17 19 Soliris 1,076 2 (25) (26) 298 2 (35) (35) Strensiq 1,641 4 38 37 588 4 33 34 Koselugo 585 1 17 15 238 1 6 9 Other Rare Disease 226 - 28 25 77 - 20 24 Rare Disease PR 7,544 16 12 11 2,633 16 9 10 Other Medicines PR 717 1 (5) (6) 231 1 (3) (3) Product Revenue 46,768 100 8 6 16,173 100 7 7 Alliance Revenue included above: Enhertu 1,670 4 29 27 612 4 34 34 Tezspire 614 1 36 35 242 1 44 44 Beyfortus 279 1 11 11 156 1 11 10 Datroway 164 - >4x >4x 71 - >2x >2x Other royalty revenue 76 - 8 8 25 - 8 4 Other Alliance Revenue 3 - (16) (16) 1 - 3 3 Alliance Revenue 2,806 6 33 32 1,107 7 36 36 Revenue drivers
Page 7
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 7 Table 4: Collaboration Revenue 9M 2026 % Change Q3 2026 % Change $m Actual CER $m Actual CER Farxiga: sales milestones 80 (2) (1) 36 >6x >7x Crestor: sales milestones 32 n/m n/m - n/m n/m Others 1 (89) (87) - n/m n/m Collaboration Revenue 113 22 23 36 >3x >3x Table 5: Total Revenue by Therapy Area 9M 2026 % Change Q3 2026 % Change $m % Total Actual CER $m % Total Actual CER Oncology 21,889 47 18 16 7,765 48 17 17 - Cardiovascular, Renal & Metabolism 8,728 19 (11) (14) 2,639 16 (18) (18) - Respiratory & Immunology 7,268 16 12 10 2,518 16 11 11 - Infectious Disease 735 2 (11) (12) 423 3 2 1 BioPharmaceuticals 16,731 36 (2) (5) 5,580 34 (5) (6) Rare Disease 7,544 16 12 11 2,633 16 9 10 Other Medicines 717 2 (6) (8) 231 1 (5) (5) Total Revenue 46,881 100 8 7 16,209 100 7 7 Table 6: Total Revenue by region 9M 2026 % Change Q3 2026 % Change $m % Total Actual CER $m % Total Actual CER US 19,789 42 7 7 6,899 43 5 5 - Emerging Markets ex. China 7,085 15 11 8 2,276 14 4 4 - China 5,430 12 3 (3) 1,920 12 9 3 Emerging Markets 12,515 27 7 3 4,196 26 6 4 Europe 10,528 22 15 10 3,706 23 11 12 Established RoW 4,049 9 4 7 1,408 9 4 11 Total Revenue 46,881 100 8 7 16,209 100 7 7 Table 7: Product Revenue by region 9M 2026 % Change Q3 2026 % Change $m % Total Actual CER $m % Total Actual CER US 19,788 42 7 7 6,899 43 5 5 - Emerging Markets ex. China 7,085 15 11 8 2,276 14 4 4 - China 5,430 12 3 (3) 1,920 12 9 3 Emerging Markets 12,515 27 7 3 4,196 26 6 4 Europe 10,528 23 15 10 3,706 23 11 12 Established RoW 3,937 8 3 7 1,372 8 3 9 Total Product Revenue 46,768 100 8 6 16,173 100 7 7
Page 8
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 8 Total Revenue by Medicine Oncology Tagrisso 9M 2026 $m Total Revenue % Change Actual CER Strong demand growth across indications and key regions, positioned as backbone across all stages of EGFRm NSCLC. Leading combination in 1L NSCLC (FLAURA2) US 2,467 11 11 Robust underlying demand Emerging Markets 1,656 10 6 More competitive environment in China in a slowing EGFRm TKI market Europe 1,169 13 8 Established RoW 570 (3) 1 Recent competitor entrant Total 5,862 10 8 Imfinzi 9M 2026 $m Total Revenue % Change Actual CER Strong demand growth across all regions from existing indications and new launches US 3,128 26 26 Demand growth led by new GI and GU launches (MATTERHORN, NIAGARA) Emerging Markets 627 35 33 Strong growth in GI (HIMALAYA, TOPAZ) including new launches (MATTERHORN) Europe 1,210 38 31 Early momentum for new lung (ADRIATIC), GI (MATTERHORN) and GU (NIAGARA) launches Established RoW 573 17 23 Demand growth from new launches across GYN (DUO-E), GU (NIAGARA) and lung (ADRIATIC, AEGEAN) Total 5,538 28 27 Calquence 9M 2026 $m Total Revenue % Change Actual CER Sustained BTKi leadership in front-line CLL with launch momentum across finite use for 1L CLL (AMPLIFY) and 1L MCL (ECHO) US 1,982 16 16 Strong demand growth from ongoing leadership in front-line CLL BTKi market Emerging Markets 214 31 25 Europe 690 21 16 Rapid AMPLIFY adoption across key markets and further expansion in 1L MCL Established RoW 123 6 6 Total 3,009 18 16 Lynparza 9M 2026 $m Total Revenue % Change Actual CER Global leadership in mature first-generation PARPi market, volume growth offset by pricing in some markets US 1,012 (4) (4) Demand growth offset by gross to net adjustments Emerging Markets 507 4 (1) Affected by generic competition in China and VBP implementation Europe 710 6 1 Stable volumes Established RoW 192 - 3 Total 2,421 1 (2) Enhertu Combined sales of Enhertu, recorded by Daiichi Sankyo and AstraZeneca, amounted to $4,675m in 9M 2026 (9M 2025: $3,575m). US in-market sales, recorded by Daiichi Sankyo, amounted to $2,329m in 9M 2026 (9M 2025: $1,734m). For periods up to and including Q3 2025, AstraZeneca’s mid-single-digit percentage royalty on Daiichi Sankyo's sales in Japan is recorded in Europe; from Q4 2025 this royalty is recorded in Established RoW. 9M 2026 $m Total Revenue % Change Actual CER Standard-of-care in HER2-positive (DESTINY-Breast03) and HER2-low (DESTINY- Breast04) metastatic breast cancer, early uptake in other cancers US 1,122 35 35 Ongoing adoption in 1L HER2-positive breast cancer (DESTINY-Breast09) and early uptake following early breast cancer launches (DESTINY-Breast05, DESTINY- Breast11) Emerging Markets 849 44 41 Broader adoption and improved access across regions Europe 596 22 15 Further demand growth in chemotherapy naïve HER2-low breast cancer Established RoW 121 91 90 Total 2,688 36 33
Page 9
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 9 Other Oncology medicines 9M 2026 $m Total Revenue % Change Actual CER Zoladex 968 9 5 Growth across Emerging Markets, partly offset by divestment of rights in Japan in May 2026 Truqap 641 30 29 Achieved peak share in US in second-line biomarker-altered metastatic breast cancer; Q3 2026 affected by US destocking following bottle to blister transition Imjudo 263 4 4 Continued GI (HIMALAYA) growth ex-US and China launch in Q3 2026, offset by lower demand in some markets Datroway 176 >4x >4x Continued uptake in breast cancer with early adoption in 1L TNBC (TROPION- Breast02), and EGFRm later-line lung cancer Combined global sales by AstraZeneca and Daiichi Sankyo: $413m (9M 2025: $115m) Etcamah 10 n/m n/m Initial uptake following US launch (SERENA-6) Other Oncology 313 (3) (4) Generic erosion across markets Other Oncology includes $14m of Total Revenue from Orpathys, partnered with HUTCHMED and $3m of Total Revenue from Zegfrovy BioPharmaceuticals – Cardiovascular, Renal & Metabolism Farxiga 9M 2026 $m Total Revenue % Change Actual CER Growth impacted by US LoE and China VBP US 795 (36) (36) Multiple generics launched in Q2 2026 Emerging Markets 2,200 (16) (21) Affected by generic competition, VBP implementation in China in Q1 2026 and unfavourable tender timing in some Emerging Markets Europe 2,385 11 6 Demand growth partly offset by generic entry in the UK in Q3 2025 Established RoW 303 (27) (25) Generic T2D entry in Japan in Q4 2025. Milestone receipts in Q1 and Q3 2026 Total 5,683 (12) (15) Other CVRM medicines 9M 2026 $m Total Revenue % Change Actual CER Crestor 1,050 11 8 Growth driven by Emerging Markets Lokelma 638 23 23 Growth in all major regions Seloken 519 11 6 Growth driven by Emerging Markets Brilinta 261 (61) (62) Decline driven by generic entry in the US and Europe in Q2 2025 Wainua 189 33 33 Demand growth in ATTR-PN and geographic expansion roxadustat 78 (66) (68) Affected by generic competition in China and VBP implementation in Q1 2026 Baxfendy 12 n/m n/m US launch in hypertension in Q2 2026 Other CVRM 298 (29) (30) Generic erosion
Page 10
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 10 BioPharmaceuticals - Respiratory & Immunology Symbicort 9M 2026 $m Total Revenue % Change Actual CER Market leader in ICS/LABA class with increasing generic competition US 772 (15) (15) Demand for brand offset by price pressure; launch of additional generic in market Emerging Markets 653 5 1 Europe 425 5 (1) Established RoW 234 (5) (7) Total 2,084 (4) (7) Fasenra 9M 2026 $m Total Revenue % Change Actual CER Continued severe eosinophilic asthma market share leadership in IL-5 class, further fuelled by accelerated EGPA and HES indication launches US 949 7 7 Strong demand with IL-5 class leadership Emerging Markets 149 85 78 Strong China uptake post Q1 2026 NRDL listing with growth in other key markets Europe 389 11 5 Increased leadership in severe eosinophilic asthma partially offset by pricing Established RoW 168 26 30 Strong growth supported by EGPA in Japan Total 1,655 14 13 Breztri 9M 2026 $m Total Revenue % Change Actual CER Fastest growing medicine within the expanding FDC triple class (ICS/LABA/LAMA) US 479 4 4 Share growth in COPD and asthma launch offset by gross-to-net adjustments Emerging Markets 329 38 31 Market share leadership within FDC triple class in China Europe 183 34 28 Sustained growth from market share gains Established RoW 82 19 21 Total 1,073 18 16 Tezspire Combined sales of Tezspire, recorded by Amgen and AstraZeneca, amounted to $1,876m in 9M 2026 (9M 2025: $1,321m). 9M 2026 $m Total Revenue % Change Actual CER Sustained demand growth in severe asthma with launch momentum across multiple markets US 614 36 35 Continued strong demand growth in severe asthma and launch of CRSwNP Emerging Markets 64 >2x >2x Strong continued uptake Europe 322 56 49 Continued new-to-brand leadership across multiple markets and market growth Established RoW 123 43 48 Total 1,123 46 44 Other R&I medicines 9M 2026 $m Total Revenue % Change Actual CER Saphnelo 615 27 27 Strong demand growth fuelled by s.c. launches Pulmicort 378 6 2 Emerging Market growth offset by pressure in Europe and Established RoW Airsupra 129 12 13 US demand volume growth partially offset by pricing pressures Other R&I 211 (9) (11) BioPharmaceuticals – Infectious Disease Total Revenue for Beyfortus reflects the sum of Product Sales from AstraZeneca’s sales of manufactured product to Sanofi, and Alliance Revenue from AstraZeneca’s share of gross profits and royalties on sales in major markets outside the US. 9M 2026 $m Total Revenue % Change Actual CER Beyfortus 427 (10) (10) Partner’s adjustment of inventory levels FluMist 172 30 29 Other ID 136 (38) (41) Other includes Synagis, which declined due to competition from Beyfortus
Page 11
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 11 Rare Disease Ultomiris Total Revenue for Ultomiris includes sales of Voydeya, which is approved as an add-on treatment to Ultomiris and Soliris for the ~20‑30% of PNH patients who experience clinically significant EVH. 9M 2026 $m Total Revenue % Change Actual CER Growth due to patient demand, both naïve to C5 medicines and conversion from Soliris across all indications (gMG, NMOSD, aHUS and PNH) US 2,190 12 12 Demand growth across indications, including within the competitive gMG and PNH landscapes Emerging Markets 306 73 73 Expansion into new markets and growth in patient demand Europe 915 19 14 Demand growth following launches; competition in gMG and PNH Established RoW 605 11 16 Continued conversion and strong patient demand Total 4,016 16 16 Soliris 9M 2026 $m Total Revenue % Change Actual CER Decline driven by conversion of patients to Ultomiris across all indications US 595 (30) (30) Affected by biosimilar pressure Emerging Markets 311 (5) (7) Europe 89 (44) (47) Affected by biosimilar pressure in PNH and aHUS Established RoW 81 (24) (23) Total 1,076 (25) (26) Strensiq 9M 2026 $m Total Revenue % Change Actual CER Growth driven by continued HPP patient demand US 1,332 40 40 Emerging Markets 111 81 67 Continued launches in new markets Europe 104 17 12 Demand growth and improved access following new launches Established RoW 94 11 17 Total 1,641 38 37 Other Rare Disease medicines 9M 2026 $m Total Revenue % Change Actual CER Koselugo 585 17 15 Continued patient demand, strong uptake following launch of adult indication. Q3 2026 benefitted from tender order timing in Emerging Markets Other Rare Disease 226 28 25 Other Rare Disease medicines include Kanuma, and Beyonttra (JP only) Other Medicines 9M 2026 $m Total Revenue % Change Actual CER Other Medicines 717 (6) (8) Generic erosion
Page 12
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 12 This section covers R&D events and milestones that occurred from 27 July 2026 up to and including 29 October 2026. A comprehensive view of AstraZeneca's pipeline of medicines in human trials can be found in the latest Clinical Trials Appendix, available on AstraZeneca’s investor relations webpage. The Clinical Trials Appendix includes tables with details of the ongoing clinical trials for AstraZeneca medicines and new molecular entities in the pipeline. Oncology AstraZeneca presented new data across its diverse portfolio of cancer medicines at two major medical congresses since the prior results announcement: the IASLC 2026 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology Congress 2026 (ESMO). Across the two meetings, more than 140 abstracts were presented featuring 27 approved and potential new medicines including 38 oral presentations. Datroway Approval EU TROPION-Breast02 July 2026 As monotherapy for the 1st-line treatment of adult patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy. Approval JP TROPION-Breast02 September 2026 New disclosure 1st-line treatment of unresectable or metastatic TNBC not candidates for PD-1/PD-L1 inhibitor therapy. Approval CN TROPION-Breast02 October 2026 New disclosure For patients with unresectable or metastatic TNBC not candidates for PD-1/PD-L1 inhibitor therapy. Enhertu Phase III readout and data presentation WCLC DESTINY-Lung04 August/September 2026 Positive results from the DESTINY-Lung04 Phase III trial showed Enhertu reduced the risk of disease progression or death by 37% versus pembrolizumab plus chemotherapy (HR 0.63; 95% CI 0.50-0.79; p<0.0001) as 1st-line treatment of patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous NSCLC. Median PFS was 14.3 months with Enhertu compared to 8.3 months for pembrolizumab plus chemotherapy. Approval CN DESTINY-Breast09 August 2026 New disclosure In combination with pertuzumab for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. Approval EU DESTINY-Breast09 September 2026 In combination with pertuzumab for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. Approval JP DESTINY-Breast09 September 2026 New disclosure In combination with pertuzumab for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. Approval CN DESTINY-Breast05 October 2026 New disclosure Adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. Approval CN DESTINY- PanTumor02, DESTINY-Lung01, DESTINY-CRC02 and DESTINY- PanTumor03 October 2026 New disclosure Unresectable or metastatic solid tumours with HER2 expression (IHC 3+) who have received prior treatment or have no satisfactory alternative treatment options. Approval EU DESTINY-Breast05 October 2026 As monotherapy for the adjuvant treatment of adult patients with resected HER2- positive breast cancer who have residual invasive disease after neoadjuvant taxane- based and HER2-targeted treatment. R&D progress
Page 13
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 13 Etcamah (camizestrant) Approval US SERENA-6 September 2026 In combination with a CDK4/6 inhibitor (abemaciclib, palbociclib or ribociclib) for HR- positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorised test. Phase III readout SERENA-4 September 2026 The SERENA-4 Phase III trial of Etcamah in combination with palbociclib did not meet the primary endpoint of PFS, however a numerical improvement was observed in the upfront 1st-line treatment of patients with ER-positive, HER2-negative advanced breast cancer who have not received any systemic treatment for advanced disease. The trial evaluated the Etcamah combination versus treatment with an aromatase inhibitor (anastrozole) in combination with palbociclib. Imfinzi Approval JP POTOMAC August 2026 New disclosure In combination with Bacillus Calmette-Guérin for the treatment of adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer. Phase III readout and data presentation ESMO DeLLphi-305 September/October 2026 Positive results from the DeLLphi-305 Phase III trial showed Imfinzi plus tarlatamab reduced the risk of death by 58% versus Imfinzi alone (HR 0.42; 95% CI 0.32-0.54; p<0.001) as 1st-line maintenance treatment for patients with ES-SCLC who had not progressed following standard induction treatment with Imfinzi plus platinum- etoposide chemotherapy. Median OS was 21.1 months with Imfinzi plus tarlatamab compared to 12.7 months for Imfinzi alone. CHMP opinion EU Label update September 2026 New disclosure Recommended update to the Imfinzi label reducing the infusion time from 60 to 30 minutes. Priority Review US VOLGA September 2026 Perioperative treatment with Imfinzi in combination with neoadjuvant enfortumab vedotin for patients with MIBC who are ineligible for or have declined cisplatin-based chemotherapy. Data presentation ESMO VOLGA October 2026 Positive results from a planned interim analysis of the VOLGA Phase III trial showed perioperative Imfinzi plus neoadjuvant enfortumab vedotin reduced the risk of disease progression, recurrence, not undergoing surgery or death by 49% versus radical cystectomy with or without approved adjuvant treatment (EFS HR 0.51; 95% CI 0.38-0.67; p<0.0001) in patients with MIBC who were ineligible for or had refused cisplatin-based chemotherapy. Median EFS was not reached with the Imfinzi regimen compared to 12.1 months for the comparator arm. For the key secondary endpoint of OS, the Imfinzi regimen reduced the risk of death by 42% (HR 0.58; 95% CI 0.40-0.83; p=0.0027). Lynparza Phase III readout MONO-OLA1 Q3 2026 New disclosure Positive high-level results from the MONO-OLA1 Phase III trial showed that both primary endpoints were met, with Lynparza demonstrating statistically significant improvements in PFS versus placebo in both the BRCAwt HRD-positive and BRCAwt populations when used as 1st-line maintenance treatment for patients with newly diagnosed high grade serous or endometrioid ovarian cancer. The safety profile of Lynparza observed in MONO-OLA1 was generally consistent with its known profile. AstraZeneca does not intend to progress with regulatory filings in US, Europe, China or Japan given the increasing trend towards PARP inhibitors being approved and used primarily in the BRCAm and HRD-positive settings in 1L ovarian cancer, a population where Lynparza +/- bevacizumab, is already the established standard of care.
Page 14
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 14 Tagrisso Phase III readout and data presentation ESMO SAFFRON August/October 2026 Positive results from the SAFFRON Phase III trial showed Tagrisso plus Orpathys reduced the risk of disease progression or death by 45% versus doublet platinum- based chemotherapy (HR 0.55; 95% CI 0.42-0.72; p<0.001) in patients with EGFRm locally advanced or metastatic NSCLC with high levels of MET overexpression or amplification who had progressed on prior treatment with Tagrisso. Median PFS was 7.6 months with Tagrisso plus Orpathys compared to 5.4 months for chemotherapy. For the key secondary endpoint of OS, Tagrisso plus Orpathys reduced the risk of death by 32% (HR 0.68; 95% CI 0.50-0.91; p=0.010), extending median OS by 4.9 months (17.8 versus 12.9 months). Phase III readout and data presentation ESMO SANOVO September/October 2026 Positive results from the SANOVO China-only Phase III trial showed Tagrisso plus Orpathys reduced the risk of disease progression or death by 44% versus Tagrisso alone in the intention-to-treat population (HR 0.56; 95% CI 0.43-0.74; p<0.0001) and by 55% in the high MET (IHC 3+) population (HR 0.45; 95% CI 0.31-0.66; p<0.0001) in treatment-naïve patients with EGFRm locally advanced or metastatic NSCLC and MET overexpression. Median PFS was 24.9 months with Tagrisso plus Orpathys compared to 13.8 months for Tagrisso alone in the intention-to-treat population. For the secondary endpoint of OS in the intention-to-treat population, Tagrisso plus Orpathys showed a very encouraging clinical benefit versus Tagrisso alone (HR 0.48; 95% CI 0.33-0.68), with median OS of 44.5 months compared to 34.9 months. Data presentation WCLC ADAURA September 2026 Updated exploratory results from the ADAURA Phase III trial showed Tagrisso demonstrated a sustained, clinically meaningful OS benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) EGFRm NSCLC after complete tumour resection, reducing the risk of death by 47% in the primary population (Stage II-IIIA) (HR 0.53; 95% CI 0.38-0.75) and by 48% in the overall trial population (HR 0.52; 95% CI 0.39-0.71). Truqap Regulatory update EU CAPItello-281 October 2026 New disclosure Withdrawal of the Type II variation application for Truqap in combination with abiraterone for the treatment of PTEN-deficient metastatic hormone-sensitive prostate cancer, based on the CAPItello-281 Phase III trial. sonesitatug vedotin (sone-ve) Data presentation ESMO CLARITY-Gastric01 October 2026 Positive results from a planned interim analysis of the CLARITY-Gastric01 Phase III trial showed sonesitatug vedotin reduced the risk of death by 53% versus investigator’s choice of therapy (HR 0.47; 95% CI 0.36-0.62; p<0.001) in patients with 3rd- and later-line CLDN18.2-positive advanced gastric, GEJ or oesophageal adenocarcinoma. Median OS was 10.0 months with sonesitatug vedotin compared to 5.0 months for investigator’s choice of therapy. In the overall 2nd- and later-line trial population, sonesitatug vedotin reduced the risk of death by 42% (HR 0.58; 95% CI 0.47-0.73; p<0.001); the other dual primary endpoint of PFS in this population did not reach statistical significance. volrustomig Phase III trial update eVOLVE-Lung02 August 2026 The eVOLVE-Lung02 Phase III trial of volrustomig in combination with chemotherapy versus pembrolizumab and chemotherapy as 1st-line treatment for patients with metastatic NSCLC whose tumours express PD-L1 <50% has been discontinued, following an IDMC recommendation that the combination was unlikely to meet either of the dual primary endpoints of PFS or OS in the primary analysis population of patients with PD-L1 negative tumours (<1%). The other Phase III volrustomig trials continue as planned.
Page 15
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 15 BioPharmaceuticals – Cardiovascular, Renal & Metabolism Wainua Data presentation ESC CARDIO-TTRansform August 2026 Wainua in patients with ATTR-CM did not meet the primary efficacy endpoint of the composite outcome of CV mortality and recurrent CV clinical events up to 140 weeks compared with placebo (rate ratio (RR) 0.89, 95% CI, 0.73-1.09, P=0.277). In a prespecified analysis, Wainua reduced the risk of CV death and recurrent CV events by 29% vs. placebo in patients not receiving a stabiliser at baseline (RR 0.71, 95% CI, 0.54-0.93). BioPharmaceuticals – Respiratory & Immunology Breztri (Trixeo) Approval EU (Trixeo) KALOS / LOGOS September 2026 Maintenance treatment of asthma in patients 12 years of age and older who are not adequately controlled by a combination of a medium dose inhaled corticosteroid and long-acting β₂-agonist. Approval JP (Breztri) KALOS / LOGOS September 2026 New disclosure For bronchial asthma (when a combination of an inhaled corticosteroid, a long-acting inhaled anticholinergic agent and a long-acting inhaled β₂-agonist is necessary). The intended use population includes both adults and children aged 12 years or above. Approval US (Breztri) NGP programme October 2026 New disclosure Breztri, already licensed for the treatment of COPD in adults and asthma in patients 12 years of age and older, has received approval in the US for the updated formulation containing AstraZeneca’s next-generation propellant with near-zero global warming potential. Tezspire Phase III readout and data presentation UEGW CROSSING September / October 2026 Positive results from the CROSSING Phase III trial demonstrated that treatment with Tezspire achieved histologic remission for 64.8% (210mg dose) and 68.9% (420mg dose) of patients at week 24, compared to 3.5% of patients on placebo (p<0.001). Tezspire also reduced the frequency and severity of dysphagia symptoms by 18.8 points (210mg dose; p=0.049) and 22.0 points (420mg dose, p<0.001) from baseline vs. 14.7 on placebo, as measured by the Dysphagia Symptom Questionnaire (DSQ) score, a patient-reported outcome measure. Efficacy was sustained in both doses through week 52, as measured in key secondary endpoints.
Page 16
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 16 tozorakimab Data presentation ERS OBERON / TITANIA September 2026 Positive results from the OBERON and TITANIA Phase III trials demonstrated that tozorakimab, administered once every four weeks, demonstrated a reduction in moderate and severe COPD exacerbations in the primary population of former smokers by 29% (OBERON) and 34% (TITANIA), and in the overall population of current and former smokers by 30% (OBERON) and 29% (TITANIA) compared with placebo while on inhaled standard of care. In addition, based on a pooled analysis of OBERON and TITANIA, patients on tozorakimab with a baseline blood eosinophil count of less than 150 cells/uL achieved a 23% reduction in moderate and severe exacerbations; patients at or above 150 achieved a 34% reduction; and patients at or above 300 achieved a 43% reduction. Priority Review US OBERON / TITANIA / PROSPERO August 2026 Add-on maintenance treatment for adult patients with COPD. Data presentation CHEST PROSPERO October 2026 In the PROSPERO long-term extension trial of OBERON and TITANIA, tozorakimab demonstrated a numerical, but not statistically significant, reduction in severe exacerbations (a different primary endpoint than OBERON and TITANIA) in the primary endpoint population of former smokers (21%; 0.26 vs 0.33 annualised rates; RR 0.79 (95% CI 0.61,1.01) p=0.0587). There was a nominally significant reduction in severe exacerbations in the overall population of former and current smokers (27%; 0.26 vs 0.36 annualised rates; RR 0.73 (95% CI 0.58, 0.91) p=0.0046). Consistent with the primary endpoint in the OBERON and TITANIA trials, PROSPERO, in a secondary endpoint, showed continued tozorakimab treatment maintained the reduction in moderate and severe COPD exacerbations in former smokers and the overall population at 104 weeks. The safety and tolerability profile of tozorakimab through 104 weeks in PROSPERO was consistent with the profile observed in the OBERON and TITANIA trials.
Page 17
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 17 Rare Disease Amlypave (anselamimab) Approval JP CARES September 2026 For systemic light chain (AL) amyloidosis (only in patients with predominantly kappa immunoglobulin light chain). efzimfotase alfa Data presentation ASBMR HICKORY October 2026 In the overall population, at week 25, efzimfotase alfa achieved a least squares (LS) mean difference of 17.05 metres (p=0.1675) change from baseline in the primary endpoint of 6MWT, compared to placebo. The lack of statistical significance was largely due to better-than-expected results observed in the adult-onset HPP placebo group. In a combination of prespecified subgroups of adolescents and adults with paediatric- onset HPP, efzimfotase alfa demonstrated nominally significant and clinically meaningful benefits in the primary endpoint of 6MWT, achieving an LS mean difference of 35.6 metres (nominal p=0.0386) vs placebo at week 25, as well as the key secondary endpoints of 30s-STS (LS mean difference vs placebo: 1.3; nominal p=0.0384) and BPI-SF Pain Severity (LS mean difference vs placebo: -1.0; nominal p=0.0260). Priority Review US HICKORY/MULBERRY /CHESTNUT September 2026 Patients with hypophosphatasia aged ≥2 years. Klygefa (gefurulimab) Approval JP PREVAIL September 2026 New disclosure For generalised myasthenia gravis (only for patients who are not adequately responsive to steroids or nonsteroidal immunosuppressants). CHMP opinion EU PREVAIL September 2026 Recommended as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Ultomiris Approval CN ALXN1210-PNH-323 August 2026 New disclosure For the treatment of adult and paediatric patients one month of age and older with paroxysmal nocturnal haemoglobinuria. Phase III trial update AWAKE October 2026 New disclosure AWAKE Phase III clinical trial evaluating Ultomiris in adult kidney transplant recipients who are at risk of delayed graft function has been discontinued, following an IDMC recommendation that Ultomiris was unlikely to meet the trial’s primary endpoint of time to freedom from dialysis through 90 days post-transplant versus placebo. The safety profile observed in this trial was consistent with the known profile of Ultomiris, with no new safety concerns identified. Approval US I CAN October 2026 For the reduction of proteinuria in adults with primary immunoglobulin A nephropathy who are at risk for disease progression. Priority Review US ALXN1210-TMA-314 ALX-TMA-502 September 2026 New disclosure Paediatric patients with haematopoietic stem cell transplant-associated thrombotic microangiopathy.
Page 18
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 18 Sustainability highlights AstraZeneca ranked fifth on TIME Magazine’s 2026 World’s Best Companies list - its highest position to date and the top ranking among pharmaceutical companies - based on sustainability transparency, revenue growth, and employee satisfaction. At Climate Week NYC, AstraZeneca’s delegation, led by Pam Cheng, EVP Global Operations, IT and Chief Sustainability Officer, engaged with more than 60 stakeholders, and advancing dialogues on sustainable, equitable and resilient healthcare. The Company announced the next phase of its flagship Young Health Programme in partnership with UNICEF, bringing its total investment from 2010- 2030 to more than $100 million. The programme, which supports young people in underserved communities, aims to prevent non-communicable diseases by activating young people to advance health equity and address the health impacts of climate change in more than 60 countries. Pam Cheng gave a live broadcast interview on the Company’s sustainability action at the New York Stock Exchange. Climate and nature AstraZeneca has successfully completed the transition of Breztri/Trixeo Aerosphere to its next-generation propellant (NGP) with near-zero global warming potential in 30 countries, following approvals in the UK, EU and Australia. In the US, Breztri received regulatory approval as the first inhaled respiratory medicine to use NGP. Regulatory filings have also been submitted in China and Japan. The Company officially launched CARESA (CARe pathways Environmental Sustainability Assessment) a free tool that helps healthcare professionals model the potential environmental impact of patient care pathways and explore choices that could improve health outcomes for patients and the planet. The European Network on Climate & Health Education, supported by AstraZeneca through the Sustainable Markets Initiative Health Systems Task Force which Pascal Soriot chairs, has helped 61 medical schools integrate sustainability into medical training, engaging over 3,000 faculty members and reaching 6,000 medical students to date. AstraZeneca received the My Green Lab and International Institute for Sustainable Laboratories (I2SL) 2026 Freezer Challenge Award for the Biotech and Pharmaceutical sector for the third time. The Freezer Challenge is a global initiative that promotes more sustainable laboratory operations through improved freezer and cold storage management, helping reduce energy use and improve efficiency. In addition, in the UK, AstraZeneca maintained the highest achievable rating, Level 4, in the NHS Evergreen Sustainable Supplier Assessment for 2026–2027. Health equity A new report, Addressing Inequalities in COPD and Lung Cancer: A Framework for Action, was launched to help policymakers and health system leaders address inequalities in care. The report was informed by a literature review and international expert input, including from Brazil, Italy, Saudi Arabia, Spain and Vietnam, and the London School of Economics (LSE Health). In the US, AstraZeneca held community engagement events in Baltimore and Houston to increase awareness of lung health and improve understanding of clinical research. Through Cancer Care Africa (CCA), AstraZeneca advanced patient support, evidence generation and clinical capacity across several African countries. This includes digitalising the ‘Sanady’ patient support programme in Morocco; generating evidence in Egypt on the potential of AI-supported triage; publishing national lung cancer registry data in Algeria; and strengthening respiratory care capabilities in Kenya through training in pleural procedures, bronchoscopy and endobronchial ultrasound. Healthy Heart Africa (HHA) partnered with Kenya’s Ministry of Health to launch the country’s first National CKD Guidelines and the second phase of the National CKD Registry. Since May 2025, HHA has screened over 11,000 high-risk individuals across Kenya for CKD. Uganda’s Ministry of Health launched HHA-supported CKD Guidelines. Health systems resilience AstraZeneca continued to advance its work to strengthen health systems through the Partnership for Health System Sustainability and Resilience (PHSSR), which has now collaborated with 36 countries. Policy roadmaps on early action on NCDs were launched in seven countries, convening government representatives, policymakers and patient groups to help unlock system-level changes, including to advance and accelerate screening programs, early detection capability and sustainable funding for innovative medicines. In Q3, launches in Spain and Greece convened government representatives, policymakers and patient groups to unlock system-level change based on the roadmap’s recommendations. Spain’s State Secretary for Health spoke at the roadmap launch at the Congress of Deputies. In France, PHSSR brought together more than 50 participants to discuss health system sustainability and resilience, including the former French Minister for Solidarity and Health. PHSSR also engaged stakeholders in Mexico on research recommendations, and Germany’s Monitor Versorgungsforschung, a peer-reviewed healthcare research journal, published an article examining the PHSSR Synthesis Report and its comparison of eight advanced health systems. Sustainability
Page 19
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 19 Reporting currency All narrative on growth and results in this section is based on actual exchange rates, and financial figures are in US$ millions ($m), unless stated otherwise. Reporting period The performance shown in this announcement covers the nine-month period to 30 September 2026 ('9M 2026') compared to the nine-month period to 30 September 2025 (‘9M 2025’), and the three-month period to 30 September 2026 ('the quarter' or 'Q3 2026') compared to the three-month period to 30 September 2025 (‘Q3 2025’), unless stated otherwise. Non-GAAP financial measures Core financial measures, EBITDA, Net debt, Core Tax rate and CER are non-GAAP financial measures because they cannot be derived directly from the Group's Condensed consolidated financial statements. Management believes that these non- GAAP financial measures, when provided in combination with Reported results, provide investors and analysts with helpful supplementary information to better understand the financial performance and position of the Group on a comparable basis from period to period. These non-GAAP financial measures are not a substitute for, or superior to, financial measures prepared in accordance with GAAP. Non-GAAP financial measures (cont.) Core financial measures are adjusted to exclude certain significant items: – Charges and provisions related to our global restructuring programmes, which includes charges that relate to the impact of restructuring programmes on our capitalised manufacturing assets and IT assets – Amortisation and impairment of intangible assets, including impairment reversals but excluding any charges relating to IT assets – Other specified items, principally comprising acquisition-related costs and credits, which include the imputed finance charges and fair value movements relating to contingent consideration on business combinations, imputed finance charges and remeasurement adjustments on certain other payables arising from intangible asset acquisitions, remeasurement adjustments relating to certain other payables, debt items assumed from the Alexion acquisition and legal settlements – The tax effects of the adjustments above are excluded from the Core Tax charge Details on the nature of Core financial measures are provided on page 53 of the Annual Report and Form 20-F Information 2025. Reference should be made to the Reconciliation of Reported to Core financial measures table included in the Financial Performance section in this announcement. Definitions Gross Margin is defined as Gross Profit as a percentage of Total Revenue. EBITDA is defined as Reported Profit before tax after adding back Net finance expense, results from Joint ventures and associates and charges for Depreciation, amortisation and impairment. Reference should be made to the Reconciliation of Reported Profit before tax to EBITDA included in the Financial Performance section in this announcement. Operating Margin is defined as Operating profit as a percentage of Total Revenue. Net debt is defined as Interest-bearing loans and borrowings and Lease liabilities, net of Cash and cash equivalents, Other investments, and Net derivative financial instruments. Reference should be made to Note 3 'Net debt', included in the Notes to the Interim financial statements in this announcement. The Company strongly encourages investors and analysts not to rely on any single financial measure, but to review AstraZeneca's financial statements, including the Notes thereto, and other available Company reports, carefully and in their entirety. Due to rounding, the sum of a number of dollar values and percentages in this announcement may not agree to totals. Operating and financial review
Page 20
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 20 Table 8: Reported Profit and Loss 9M 2026 9M 2025 % Change Q3 2026 Q3 2025 % Change $m $m Actual CER $m $m Actual CER - Product Sales 43,962 41,035 7 5 15,066 14,365 5 5 - Alliance Revenue 2,806 2,108 33 32 1,107 815 36 36 Product Revenue 46,768 43,143 8 6 16,173 15,180 7 7 Collaboration Revenue 113 93 22 23 36 11 >3x >3x Total Revenue 46,881 43,236 8 7 16,209 15,191 7 7 Cost of sales (8,147) (7,515) 8 3 (2,946) (2,801) 5 2 Gross profit 38,734 35,721 8 7 13,263 12,390 7 8 Distribution expense (437) (426) 3 (1) (151) (148) 3 2 R&D expense (11,439) (10,370) 10 9 (3,894) (3,663) 6 7 SG&A expense (15,679) (14,441) 9 7 (5,108) (5,085) - - Other operating income & expense 618 281 >2x >2x 277 89 >3x >3x Operating profit 11,797 10,765 10 10 4,387 3,583 22 26 Net finance expense (1,085) (985) 10 9 (410) (349) 17 22 Joint ventures and associates (41) (7) >5x >5x (19) 10 n/m n/m Profit before tax 10,671 9,773 9 10 3,958 3,244 22 25 Taxation (1,966) (1,869) 5 6 (842) (709) 19 22 Tax rate 18% 19% 21% 22% Profit after tax 8,705 7,904 10 11 3,116 2,535 23 26 Earnings per share $5.62 $5.10 10 11 $2.02 $1.64 23 26 Table 9: Reconciliation of Reported Profit before tax to EBITDA 9M 2026 9M 2025 % Change Q3 2026 Q3 2025 % Change $m $m Actual CER $m $m Actual CER Reported Profit before tax 10,671 9,773 9 10 3,958 3,244 22 25 Net finance expense 1,085 985 10 9 410 349 17 22 Joint ventures and associates 41 7 >5x >5x 19 (10) n/m n/m Depreciation, amortisation and impairment 4,900 4,222 16 15 1,605 1,549 4 4 EBITDA 16,697 14,987 11 11 5,992 5,132 17 19 Table 10: Reconciliation of Reported to Core financial measures: 9M 2026 For the nine months ended 30 September Reported Restructuring Intangible Asset Amortisation & Impairments Other Core % Change $m $m $m $m $m Actual CER Gross profit 38,734 13 19 3 38,769 9 7 - Gross Margin 83% 83% - +1pp Distribution expense (437) 1 - - (436) 2 (1) R&D expense (11,439) 157 511 3 (10,768) 7 5 - R&D % of Total Revenue 24% 23% - - SG&A expense (15,679) 258 3,194 409 (11,818) 7 4 - SG&A % of Total Revenue 33% 25% - +1pp Total operating expense (27,555) 416 3,705 412 (23,022) 7 5 Other operating income & expense 618 (1) - 1 618 >2x >2x Operating profit 11,797 428 3,724 416 16,365 14 14 - Operating Margin 25% 35% +2pp +2pp Net finance expense (1,085) - - 93 (992) 21 20 Taxation (1,966) (103) (738) (122) (2,929) 11 12 EPS $5.62 $0.21 $1.93 $0.24 $8.00 14 14 Financial performance
Page 21
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 21 Table 11: Reconciliation of Reported to Core financial measures: Q3 2026 For the quarter ended 30 September Reported Restructuring Intangible Asset Amortisation & Impairments Other Core % Change $m $m $m $m $m Actual CER Gross profit 13,263 16 3 - 13,282 7 8 - Gross Margin 82% 82% - +1pp Distribution expense (151) 1 - - (150) 2 1 R&D expense (3,894) 100 147 2 (3,645) 3 3 - R&D % of Total Revenue 24% 22% +1pp +1pp SG&A expense (5,108) 152 1,038 9 (3,909) 2 2 - SG&A % of Total Revenue 32% 24% +1pp +1pp Total operating expense (9,153) 253 1,185 11 (7,704) 2 2 Other operating income & expense 277 (1) - 1 277 >2x >2x Operating profit 4,387 268 1,188 12 5,855 17 20 - Operating Margin 27% 36% +3pp +4pp Net finance expense (410) - - 39 (371) 22 27 Taxation (842) (63) (224) (11) (1,140) 14 16 EPS $2.02 $0.13 $0.62 $0.02 $2.79 17 19 Profit and Loss drivers Gross profit The movement in Gross Margin (Reported and Core) in 9M 2026 was a result of: – Positive effects from geographic mix – The changing mix of Product Sales with profit sharing arrangements (Lynparza, Enhertu, Datroway, Tezspire, plus Koselugo in the prior year period) reduces Gross Margin because AstraZeneca records Product Sales in certain markets and pays away a share of the gross profits to its collaboration partners. The profit share paid to partners is recorded in AstraZeneca’s Cost of sales line – Pricing adjustments to medicines that have reached the end of their exclusivity periods, and implementation of the US government agreement announced in 2025 Variations in Gross Margin performance between periods can continue to be expected due to product seasonality, foreign exchange fluctuations, and other effects. R&D expense The increase in R&D expense (Reported and Core) in the period was driven by: – Positive data readouts for high-value pipeline opportunities that have ungated late-stage trials – Investment in platforms, new technology and capabilities to enhance R&D capabilities – Addition of R&D projects following completion of previously announced business development activity – The change in Reported R&D expense also reflects impairment charges of $483m recorded against intangible assets in 9M 2026 SG&A expense The increase in SG&A expense (Reported and Core) in the period was driven primarily by ongoing and future launches and to support continued growth in existing brands. Other operating income and expense The increase in Other operating income and expense (Reported and Core) was driven by increased royalty income and disposals of financial interests in mature medicines such as Zoryve. Net finance expense Core Net finance expense increased 21% (20% at CER) in 9M 2026, principally due to higher interest expense on short-term borrowings, lower interest income on short-term deposits and higher discount unwind on lease liabilities, also due to the prior year benefitting from adjustments relating to settlements with tax authorities. Taxation The effective Reported and Core tax rates in 9M 2026 were 18% and 19% respectively (9M 2025: both 19%). The cash tax paid in 9M 2026 was $2,634m (9M 2025: $2,193m), representing 25% of Reported Profit before tax (9M 2025: 22%).
Page 22
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 22 Cash Flow Table 12: Cash Flow summary: 9M 2026 For the nine months ended 30 September 9M 2026 $m 9M 2025 $m Change $m Reported Operating profit 11,797 10,765 1,032 Depreciation, amortisation and impairment 4,900 4,222 678 Movement in working capital and short-term provisions (1,730) 64 (1,794) Gains on disposal of intangible assets (156) (118) (38) Fair value movements on contingent consideration arising from business combinations (15) (29) 14 Non-cash and other movements (125) 591 (716) Interest paid (1,147) (1,069) (78) Taxation paid (2,634) (2,193) (441) Net cash inflow from operating activities 10,890 12,233 (1,343) Net cash outflow from investing activities (6,589) (5,362) (1,227) Net cash outflow from financing activities (2,066) (4,262) 2,196 Net increase in cash and cash equivalents in the period 2,235 2,609 (374) Net cash flow The decrease in Net cash inflow from operating activities of $1,343m was primarily driven by Movement in working capital and short-term provisions including the impact of Farxiga loss of exclusivity in the US, higher taxation paid and foreign exchange fluctuations, offset by increased Operating profit. The increase in Net cash outflow from investing activities of $1,227m was primarily driven by increased Purchase of intangible assets, including an upfront payment of $1,104m to CSPC Pharmaceuticals during Q2 2026. The decrease in Net cash outflow from financing activities of $2,196m was primarily driven by the issue of new long- term loans of $4,972m, partially offset by the repayment of long-term loans of $2,456m in 9M 2026. There were no significant issuances or repayments of long-term loans in 9M 2025. Capital expenditure Capital expenditure on Property, plant and equipment and software-related intangible assets amounted to $2,284m in 9M 2026 (9M 2025: $2,091m). The increase of capital expenditure in 9M 2026 was driven by investment in several major manufacturing projects and continued investment in technology upgrades. Net debt Net debt increased by $2,459m in the nine months to 30 September 2026 to $25,833m. Details of the committed undrawn bank facilities are disclosed within the Going concern section of Note 1. Details of the Company's solicited credit ratings and further details on Net debt are disclosed in Note 3. Net debt Table 13: Net debt summary At 30 Sep 2026 $m At 31 Dec 2025 $m At 30 Sep 2025 $m Cash and cash equivalents 7,936 5,711 8,143 Other investments 230 30 39 Cash and investments 8,166 5,741 8,182 Overdrafts and short-term borrowings (473) (644) (622) Commercial paper (1,619) - (1,091) Lease liabilities (2,777) (1,803) (1,758) Current instalments of loans (2,857) (2,460) (4,461) Non-current instalments of loans (26,465) (24,715) (24,700) Interest-bearing loans and borrowings (Gross debt) (34,191) (29,622) (32,632) Net derivatives 192 507 485 Net debt (25,833) (23,374) (23,965)
Page 23
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 23 Summarised financial information for guarantee of securities of subsidiaries AstraZeneca Finance LLC ("AstraZeneca Finance") is the issuer of 4.800% Notes due 2027, 4.875% Notes due 2028, 1.750% Notes due 2028, 4.850% Notes due 2029, 4.900% Notes due 2030, 4.900% Notes due 2031, 2.250% Notes due 2031, 4.000% Notes due 2031, 4.875% Notes due 2033, 4.300% Notes due 2033, 5.000% Notes due 2034 and 4.600% Notes due 2036 (the "AstraZeneca Finance USD Notes"). Each series of AstraZeneca Finance USD Notes has been fully and unconditionally guaranteed by AstraZeneca PLC. AstraZeneca Finance is 100% owned by AstraZeneca PLC and each of the guarantees issued by AstraZeneca PLC is full and unconditional and joint and several. The AstraZeneca Finance USD Notes are senior unsecured obligations of AstraZeneca Finance and rank equally with all of AstraZeneca Finance's existing and future senior unsecured and unsubordinated indebtedness. The guarantee by AstraZeneca PLC of the AstraZeneca Finance USD Notes is the senior unsecured obligation of AstraZeneca PLC and ranks equally with all of AstraZeneca PLC's existing and future senior unsecured and unsubordinated indebtedness. Each guarantee by AstraZeneca PLC is effectively subordinated to any secured indebtedness of AstraZeneca PLC to the extent of the value of the assets securing such indebtedness. The AstraZeneca Finance USD Notes are structurally subordinated to indebtedness and other liabilities of the subsidiaries of AstraZeneca PLC, none of which guarantee the AstraZeneca Finance USD Notes. AstraZeneca PLC manages substantially all of its operations through divisions, branches and/or investments in subsidiaries and affiliates. Accordingly, the ability of AstraZeneca PLC to service its debt and guarantee obligations is also dependent upon the earnings of its subsidiaries, affiliates, branches and divisions, whether by dividends, distributions, loans or otherwise. Please refer to the Consolidated financial statements of AstraZeneca PLC in our Annual Report on Form 20-F as filed with the SEC and information contained herein for further financial information regarding AstraZeneca PLC and its consolidated subsidiaries. For further details, terms and conditions of the AstraZeneca Finance USD Notes please refer to AstraZeneca PLC's reports on Form 6-K furnished to the SEC on 26 February 2026, 22 February 2024, 3 March 2023 and 28 May 2021. Pursuant to Rule 13-01 and Rule 3-10 of Regulation S-X under the Securities Act of 1933, as amended (the "Securities Act"), we present below the summary financial information for AstraZeneca PLC, as Guarantor, excluding its consolidated subsidiaries, and AstraZeneca Finance, as the issuer, excluding its consolidated subsidiaries. The following summary financial information of AstraZeneca PLC and AstraZeneca Finance is presented on a combined basis and transactions between the combining entities have been eliminated. Financial information for non- guarantor entities has been excluded. Intercompany balances and transactions between the obligor group and the non- obligor subsidiaries are presented on separate lines. Obligor group summarised statements Table 14: Obligor group summarised Statement of comprehensive income: 9M 2026 For the nine months ended 30 September 2026 $m 2025 $m Total Revenue - - Gross profit - - Operating loss (5) - Loss for the period (832) (957) Transactions with subsidiaries that are not issuers or guarantors 6,740 6,509 Table 15: Obligor group summarised Statement of financial position At 30 Sep 2026 $m At 30 Sep 2025 $m Current assets 129 13 Non-current assets 11 141 Current liabilities (4,704) (5,976) Non-current liabilities (26,568) (24,704) Amounts due from subsidiaries that are not issuers or guarantors 25,450 21,519 Amounts due to subsidiaries that are not issuers or guarantors - -
Page 24
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 24 Capital allocation The Group’s capital allocation priorities include: investing in the business and pipeline; maintaining a strong, investment- grade credit rating; pursuing potential value-enhancing business development opportunities; and supporting the progressive dividend policy. In approving the declaration of dividends, the Board considers both the liquidity of the Company and the level of reserves legally available for distribution. In FY 2026, the Company intends to increase the annual dividend declared to $3.30 per share. Dividends are paid to shareholders from AstraZeneca PLC, a Group holding company with no direct operations. The ability of AstraZeneca PLC to make shareholder distributions is dependent on the creation of profits for distribution and the receipt of funds from subsidiary companies. The consolidated Group reserves set out in the Condensed consolidated statement of financial position do not reflect the profit available for distribution to the shareholders of AstraZeneca PLC. In FY 2025, capital expenditure on Property, plant and equipment and Software-related intangible assets amounted to $3,270m. In FY 2026 the Group expects to increase expenditure on Property, plant and equipment and Software-related intangible assets by a low-teens percentage, driven by manufacturing expansion projects and investments in systems and technology. Foreign exchange The Company's transactional currency exposures on working capital balances, which typically extend for up to three months, are hedged where practicable using forward foreign exchange contracts against the individual companies' reporting currency. Foreign exchange gains and losses on forward contracts transacted for transactional hedging are taken to profit or to Other comprehensive income if the contract is in a designated cash flow hedge. In addition, the Company's external dividend payments paid in pound sterling and Swedish krona, are fully hedged from the time of their announcement to the payment date. Table 16: Currency sensitivities Currency Primary Relevance Exchange rate vs USD (average rate in period) Annual impact of 5% strengthening vs USD1 ($m) FY 20252 YTD 20263 Change (%) Sep 20264 Change (%) Total Revenue Core Operating Profit EUR Total Revenue 0.88 0.86 3 0.87 2 499 234 CNY Total Revenue 7.19 6.82 5 6.71 7 329 178 JPY Total Revenue 149.64 158.51 (6) 156.40 (5) 179 120 GBP Operating expense 0.76 0.74 2 0.75 2 50 (180) SEK Operating expense 9.81 9.38 4 9.75 1 9 (71) Other 615 339 1. Assumes the average exchange rate vs USD in FY 2026 is 5% higher than the average rate in FY 2025. The impact data are estimates, based on best prevailing assumptions around currency profiles. 2. Based on average daily spot rates 1 January 2025 to 31 December 2025. 3. Based on average daily spot rates 1 January 2026 to 30 September 2026. 4. Based on average daily spot rates 1 September 2026 to 30 September 2026.
Page 25
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 25 Table 17: Condensed consolidated statement of comprehensive income: 9M 2026 For the nine months ended 30 September 2026 $m 2025 $m - Product Sales 43,962 41,035 - Alliance Revenue 2,806 2,108 Product Revenue 46,768 43,143 Collaboration Revenue 113 93 Total Revenue 46,881 43,236 Cost of sales (8,147) (7,515) Gross profit 38,734 35,721 Distribution expense (437) (426) Research and development expense (11,439) (10,370) Selling, general and administrative expense (15,679) (14,441) Other operating income and expense 618 281 Operating profit 11,797 10,765 Finance income 217 225 Finance expense (1,302) (1,210) Share of after tax losses in associates and joint ventures (41) (7) Profit before tax 10,671 9,773 Taxation (1,966) (1,869) Profit for the period 8,705 7,904 Other comprehensive income Items that will not be reclassified to profit and loss: Remeasurement of the defined benefit pension liability 268 116 Net gains/(losses) on equity investments measured at fair value through Other comprehensive income 529 (21) Tax expense on items that will not be reclassified to profit or loss (77) (13) 720 82 Items that may be reclassified subsequently to profit and loss: Foreign exchange arising on consolidation (862) 2,266 Foreign exchange arising on designated liabilities in net investment hedges 47 15 Fair value movements on cash flow hedges (12) 256 Fair value movements on cash flow hedges transferred to profit and loss 114 (318) Fair value movements on derivatives designated in net investment hedges (17) (7) (Costs)/gains of hedging (70) 8 Tax expense on items that may be reclassified subsequently to profit and loss (14) (50) (814) 2,170 Other comprehensive (expense)/income for the period, net of tax (94) 2,252 Total comprehensive income for the period 8,611 10,156 Profit attributable to: Owners of the Parent 8,704 7,899 Non-controlling interests 1 5 8,705 7,904 Total comprehensive income attributable to: Owners of the Parent 8,612 10,149 Non-controlling interests (1) 7 8,611 10,156 Earnings per share Basic earnings per $0.25 Ordinary Share $5.62 $5.10 Diluted earnings per $0.25 Ordinary Share $5.58 $5.06 Weighted average number of Ordinary Shares in issue (millions) 1,550 1,550 Diluted weighted average number of Ordinary Shares in issue (millions) 1,561 1,561 Interim financial statements
Page 26
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 26 Table 18: Condensed consolidated statement of comprehensive income: Q3 2026 For the quarter ended 30 September 2026 $m 2025 $m - Product Sales 15,066 14,365 - Alliance Revenue 1,107 815 Product Revenue 16,173 15,180 Collaboration Revenue 36 11 Total Revenue 16,209 15,191 Cost of sales (2,946) (2,801) Gross profit 13,263 12,390 Distribution expense (151) (148) Research and development expense (3,894) (3,663) Selling, general and administrative expense (5,108) (5,085) Other operating income and expense 277 89 Operating profit 4,387 3,583 Finance income 67 85 Finance expense (477) (434) Share of after tax (losses)/gains in associates and joint ventures (19) 10 Profit before tax 3,958 3,244 Taxation (842) (709) Profit for the period 3,116 2,535 Other comprehensive income Items that will not be reclassified to profit and loss: Remeasurement of the defined benefit pension liability 35 146 Net gains on equity investments measured at fair value through Other comprehensive income 64 104 Tax expense on items that will not be reclassified to profit or loss (26) (10) 73 240 Items that may be reclassified subsequently to profit and loss: Foreign exchange arising on consolidation (163) (198) Foreign exchange arising on designated liabilities in net investment hedges 4 5 Fair value movements on cash flow hedges 69 (17) Fair value movements on cash flow hedges transferred to profit and loss 18 (3) Fair value movements on derivatives designated in net investment hedges (21) 13 Costs of hedging (70) (2) Tax (expense)/income on items that may be reclassified subsequently to profit and loss (21) 2 (184) (200) Other comprehensive (expense)/income for the period, net of tax (111) 40 Total comprehensive income for the period 3,005 2,575 Profit attributable to: Owners of the Parent 3,117 2,533 Non-controlling interests (1) 2 3,116 2,535 Total comprehensive income attributable to: Owners of the Parent 3,006 2,575 Non-controlling interests (1) - 3,005 2,575 Earnings per share Basic earnings per $0.25 Ordinary Share $2.02 $1.64 Diluted earnings per $0.25 Ordinary Share $2.00 $1.62 Weighted average number of Ordinary Shares in issue (millions) 1,551 1,551 Diluted weighted average number of Ordinary Shares in issue (millions) 1,560 1,561
Page 27
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 27 Table 19: Condensed consolidated statement of financial position At 30 Sep 2026 At 31 Dec 2025 At 30 Sep 2025 Assets $m $m $m Non-current assets Property, plant and equipment 14,064 12,962 12,083 Right-of-use assets 2,714 1,741 1,700 Goodwill 21,157 21,242 21,219 Intangible assets 38,146 37,846 38,191 Investments in associates and joint ventures 268 302 296 Other investments 2,676 2,223 1,990 Derivative financial instruments 306 498 502 Other receivables 1,426 1,327 1,159 Income tax receivable 1,062 1,391 1,247 Deferred tax assets 6,655 5,819 6,129 88,474 85,351 84,516 Current assets Inventories 6,883 6,557 6,593 Trade and other receivables 14,736 15,177 14,338 Other investments 230 30 39 Derivative financial instruments 20 90 12 Income tax receivable 1,643 1,158 815 Cash and cash equivalents 7,936 5,711 8,143 31,448 28,723 29,940 Total assets 119,922 114,074 114,456 Liabilities Current liabilities Interest-bearing loans and borrowings (4,949) (3,104) (6,174) Lease liabilities (445) (382) (379) Trade and other payables (23,572) (25,280) (25,028) Derivative financial instruments (26) (81) (29) Provisions (654) (686) (1,176) Income tax payable (1,621) (1,084) (1,268) (31,267) (30,617) (34,054) Non-current liabilities Interest-bearing loans and borrowings (26,465) (24,715) (24,700) Lease liabilities (2,332) (1,421) (1,379) Derivative financial instruments (108) - - Deferred tax liabilities (3,617) (3,500) (3,604) Retirement benefit obligations (780) (1,105) (1,271) Provisions (988) (918) (929) Income tax payable (293) (700) (535) Other payables (2,258) (2,379) (2,013) (36,841) (34,738) (34,431) Total liabilities (68,108) (65,355) (68,485) Net assets 51,814 48,719 45,971 Equity Share capital 388 388 388 Share premium account 35,286 35,266 35,243 Other reserves 1,985 2,041 2,044 Retained earnings 14,069 10,972 8,213 Capital and reserves attributable to equity holders of the Parent 51,728 48,667 45,888 Non-controlling interests 86 52 83 Total equity 51,814 48,719 45,971
Page 28
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 28 Table 20: Condensed consolidated statement of changes in equity Share capital Share premium account Other reserves Retained earnings Total attributable to owners of the Parent Non- controlling interests Total equity $m $m $m $m $m $m $m At 1 January 2025 388 35,226 2,012 3,160 40,786 85 40,871 Profit for the period - - - 7,899 7,899 5 7,904 Other comprehensive (expense)/income - - (61) 2,311 2,250 2 2,252 Transfer to Other reserves - - 48 (48) - - - Transactions with owners Dividends - - - (4,846) (4,846) - (4,846) Dividends paid to non-controlling interests - - - - - (2) (2) Issue of Ordinary Shares - 17 - - 17 - 17 Changes in non-controlling interests - - - 8 8 (7) 1 Movement in shares held by Employee Benefit Trusts - - 45 - 45 - 45 Share-based payments charge for the period - - - 529 529 - 529 Settlement of share plan awards - - - (800) (800) - (800) Net movement - 17 32 5,053 5,102 (2) 5,100 At 30 September 2025 388 35,243 2,044 8,213 45,888 83 45,971 At 1 January 2026 388 35,266 2,041 10,972 48,667 52 48,719 Profit for the period - - - 8,704 8,704 1 8,705 Other comprehensive income/(expense) - - 27 (119) (92) (2) (94) Transfer to Other reserves - - 10 (10) - - - Transactions with owners Dividends - - - (5,002) (5,002) - (5,002) Dividends paid to non-controlling interests - - - - - (2) (2) Issue of Ordinary Shares - 20 - - 20 - 20 Changes in non-controlling interests - - - - - 37 37 Movement in shares held by Employee Benefit Trusts - - (93) - (93) - (93) Share-based payments charge for the period - - - 574 574 - 574 Settlement of share plan awards - - - (1,050) (1,050) - (1,050) Net movement - 20 (56) 3,097 3,061 34 3,095 At 30 September 2026 388 35,286 1,985 14,069 51,728 86 51,814
Page 29
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 29 Table 21: Condensed consolidated statement of cash flows: 9M 2026 For the nine months ended 30 September 2026 $m 2025 $m Cash flows from operating activities Profit before tax 10,671 9,773 Finance income and expense 1,085 985 Share of after tax losses of associates and joint ventures 41 7 Depreciation, amortisation and impairment 4,900 4,222 Movement in working capital and short-term provisions (1,730) 64 Gains on disposal of intangible assets (156) (118) Fair value movements on contingent consideration arising from business combinations (15) (29) Non-cash and other movements (125) 591 Cash generated from operations 14,671 15,495 Interest paid (1,147) (1,069) Tax paid (2,634) (2,193) Net cash inflow from operating activities 10,890 12,233 Cash flows from investing activities Acquisition of businesses, net of cash acquired1 (600) (60) Payment of contingent consideration from business combinations (290) (897) Purchase of property, plant and equipment (1,986) (1,774) Disposal of property, plant and equipment 13 10 Purchase of intangible assets (3,862) (2,844) Disposal of intangible assets 180 96 Purchase of non-current asset investments (18) (218) Disposal of non-current asset investments 3 - Movement in short-term investments, fixed deposits and other investing instruments (196) 122 Payments to associates and joint ventures (14) (10) Interest received 181 213 Net cash outflow from investing activities (6,589) (5,362) Net cash inflow before financing activities 4,301 6,871 Cash flows from financing activities Proceeds from issue of share capital 20 17 Own shares purchased by Employee Benefit Trusts (763) (508) Payments to acquire non-controlling interests - (14) Issue of loans and borrowings 4,972 9 Repayment of loans and borrowings (2,456) (20) Dividends paid (4,955) (4,968) Hedge contracts relating to dividend payments (52) 113 Repayment of obligations under leases (282) (273) Movement in short-term borrowings 1,450 1,382 Net cash outflow from financing activities (2,066) (4,262) Net increase in Cash and cash equivalents in the period 2,235 2,609 Cash and cash equivalents at the beginning of the period 5,698 5,429 Exchange rate effects (16) 42 Cash and cash equivalents at the end of the period 7,917 8,080 Cash and cash equivalents consist of: Cash and cash equivalents 7,936 8,143 Overdrafts (19) (63) 7,917 8,080 1. This item was previously named “Acquisition of subsidiaries, net of cash acquired”.
Page 30
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 30 Note 1: Basis of preparation and accounting policies These unaudited Interim financial statements for 9M and Q3 ended 30 September 2026 have been prepared in accordance with International Accounting Standard 34, ‘Interim Financial Reporting’ (IAS 34), as issued by the International Accounting Standards Board (IASB), IAS 34 as adopted by the European Union, UK- adopted IAS 34 and the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s Financial Conduct Authority and with the requirements of the Companies Act 2006 as applicable to companies reporting under those standards. The unaudited Interim financial statements for 9M and Q3 ended 30 September 2026 were approved by the Board of Directors for publication on 30 October 2026. This results announcement does not constitute statutory accounts of the Group within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The annual financial statements of the Group for the year ended 31 December 2025 were prepared in accordance with UK- adopted international accounting standards and with the requirements of the Companies Act 2006. The annual financial statements also comply fully with IFRS Accounting Standards as issued by the IASB and International Accounting Standards as adopted by the European Union. Except for the estimation of the interim income tax charge, the Interim financial statements have been prepared applying the accounting policies that were applied in the preparation of the Group’s published consolidated financial statements for the year ended 31 December 2025. The comparative figures for the financial year ended 31 December 2025 are not the Group’s statutory accounts for that financial year. Those accounts have been reported on by the Group’s auditors and have been delivered to the Registrar of Companies; their report (i) was unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006. Going concern The Group has considerable financial resources available. As at 30 September 2026, the Group has $12.8bn in financial resources (Cash and cash equivalents of $7.9bn and undrawn committed bank facilities of $4.9bn that are available until April 2031), with $5.4bn of borrowings due within one year. These facilities contain no financial covenants. The Group has assessed the prospects of the Group over a period of at least 12 months from the date of Board approval of these consolidated financial statements, with no deterioration noted requiring a further extension of this review. The Group's revenues are largely derived from sales of medicines covered by patents, which provide a relatively high level of resilience and predictability to cash inflows, although government price interventions in response to budgetary constraints are expected to continue to adversely affect revenues in some of our significant markets. The Group, however, anticipates new revenue streams from both recently launched medicines and those in development, and the Group has a wide diversity of customers and suppliers across different geographic areas. Consequently, the Directors believe that, overall, the Group is well placed to manage its business risks successfully. Accordingly, they continue to adopt the going concern basis in preparing the Interim financial statements. Legal proceedings The information contained in Note 6 updates the disclosures concerning legal proceedings and contingent liabilities in the Group's Annual Report and Form 20-F Information 2025. Notes to the Interim financial statements
Page 31
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 31 Note 2: Intangible assets An intangible asset of $946m has been recognised in Q3 2026 comprising the rights to Zegfrovy from Dizal Pharmaceutical Co., Ltd (see Note 5). During Q3, impairment charges recorded against products in development totalled $138m recorded within R&D expense. During Q2, as previously announced, the strategic collaboration and license agreement with CSPC Pharmaceuticals closed. Under this agreement, the companies will initially progress four programmes, which utilise CSPC Pharmaceuticals’ advanced AI-driven peptide drug discovery platform and their proprietary LiquidGel once-monthly dosing platform technology. AstraZeneca paid an upfront payment of $1.2bn, of which $1.1bn was capitalised within intangible assets in Q2 2026. Contingent consideration of up to $3.5bn could be paid on achievement of regulatory milestones; these potential liabilities would be recorded when the relevant recognition event for a regulatory milestone is achieved. Further contingent sales milestones, as well as tiered royalties, could be payable and would be recognised when the associated milestones are triggered. Note 3: Net debt Table 22: Net debt At 1 Jan 2026 Cash flow Non-cash and other Exchange movements At 30 Sep 2026 $m $m $m $m $m Non-current instalments of loans (24,715) (4,952) 2,979 223 (26,465) Non-current instalments of leases (1,421) - (930) 19 (2,332) Total long-term debt (26,136) (4,952) 2,049 242 (28,797) Current instalments of loans (2,460) 2,453 (2,872) 22 (2,857) Current instalments of leases (382) 368 (437) 6 (445) Commercial paper - (1,619) - - (1,619) Collateral received from derivative counterparties (473) 155 - - (318) Other short-term borrowings excluding overdrafts (158) 14 - 8 (136) Overdrafts (13) (6) - - (19) Total current debt (3,486) 1,365 (3,309) 36 (5,394) Gross borrowings (29,622) (3,587) (1,260) 278 (34,191) Net derivative financial instruments 507 457 (772) - 192 Net borrowings (29,115) (3,130) (2,032) 278 (33,999) Cash and cash equivalents 5,711 2,241 - (16) 7,936 Other investments - current 30 200 - - 230 Cash and investments 5,741 2,441 - (16) 8,166 Net debt (23,374) (689) (2,032) 262 (25,833) The table above provides an analysis of Net debt and a reconciliation of Net cash flow to the movement in Net debt. The Group monitors Net debt as part of its capital management policy as described in Note 28 of the Annual Report and Form 20-F Information 2025. Net debt is a non- GAAP financial measure. Net debt increased by $2,459m in the nine months to 30 September 2026 to $25,833m, which includes the issue of new long-term loans of $4,972m, of which $20m was received from derivative financial instruments designated as hedges of those loans, and the repayment of long- term loans of $2,456m in 9M 2026. Details of the committed undrawn bank facilities are disclosed within the going concern section of Note 1. Non-cash movements in the period include fair value adjustments under IFRS 9 'Financial Instruments'. The Group has agreements with some bank counterparties whereby the parties agree to post cash collateral on financial derivatives, for the benefit of the other, equivalent to the market valuation of the derivative positions above a predetermined threshold. The carrying value of such cash collateral held by the Group at 30 September 2026 was $318m (31 December 2025: $473m) and the carrying value of such cash collateral posted by the Group at 30 September 2026 was $181m (31 December 2025: $22m). The equivalent GAAP measure to Net debt is 'liabilities arising from financing activities', which excludes the amounts for cash and overdrafts, other investments and non-financing derivatives above. During the nine months ended 30 September 2026, there have been no changes to the Group’s solicited credit ratings. Moody’s credit ratings were long term: A1; short term: P-1. Standard and Poor’s credit ratings were long term: A+; short term: A-1.
Page 32
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 32 Note 4: Financial Instruments As detailed in the Group's most recent annual financial statements, the principal financial instruments consist of derivative financial instruments, other investments, trade and other receivables, cash and cash equivalents, trade and other payables, lease liabilities and interest-bearing loans and borrowings. The Group has certain equity investments that are categorised as Level 3 in the fair value hierarchy that are held at $605m (31 December 2025: $458m) and for which a fair value gain of $158m has been recognised in the nine months ended 30 September 2026 (9M 2025: loss of $47m). In the absence of specific market data, these unlisted investments are held at fair value based on the cost of investment and adjusted as necessary for impairments and revaluations on new funding rounds, which are seen to approximate the fair value. All other fair value gains and/or losses that are presented in Net gains/(losses) on equity investments measured at fair value through Other comprehensive income, in the Condensed consolidated statement of comprehensive income for the nine months ended 30 September 2026, are Level 1 fair value measurements, valued based on quoted prices in active markets. Financial instruments measured at fair value include $2,724m of other investments, $6,073m held in money- market funds and $192m of derivatives as at 30 September 2026. With the exception of derivatives being Level 2 fair valued, and certain equity instruments of $605m categorised as Level 3, the aforementioned balances are Level 1 fair valued. Financial instruments measured at amortised cost include $181m of cash collateral pledged to counterparties. The total fair value of Interest-bearing loans and borrowings as at 30 September 2026, which have a carrying value of $34,191m in the Condensed consolidated statement of financial position, was $32,494m. Contingent consideration arising from business combinations is fair valued using decision-tree analysis, with key inputs including the probability of success, consideration of potential delays and the expected levels of future revenues. The final contingent consideration payment of $257m relating to BMS's share of the global diabetes alliance was made in Q1 2026. Note 5: Business combinations On 31 August 2026, AstraZeneca completed the exclusive license agreement with Dizal Pharmaceutical Co., Ltd for Zegfrovy (sunvozertinib), an oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. Through this acquisition agreement, AstraZeneca has acquired worldwide rights to develop and commercialise Zegfrovy, along with China based employees and related contracts to support the manufacture of Zegfrovy. The transaction is recorded as a business combination using the acquisition method of accounting in accordance with IFRS 3 ‘Business Combinations’. Consequently, the assets acquired, and liabilities assumed are required to be recorded at fair value. Given the proximity of the acquisition to the reporting date, the purchase price allocation exercise under IFRS 3 is in process, with the following items disclosed on a provisional basis. The total consideration fair value of $946m includes upfront cash consideration of $600m, and contingent consideration of $346m. Additional future payments are contingent upon achievement of specific development, regulatory and sales-related milestones. Additionally, Dizal will receive tiered royalties on the global sales of Zegfrovy. An intangible asset of $946m has been recognised comprising the rights to Zegfrovy. Note 6: Legal proceedings and contingent liabilities AstraZeneca is involved in various legal proceedings considered typical to its business, including litigation and investigations, including Government investigations, relating to product liability, commercial disputes, infringement of intellectual property (IP) rights, the validity of certain patents, anti-trust law and sales and marketing practices. The matters discussed below constitute the more significant developments since publication of the disclosures concerning legal proceedings in the Company's Annual Report and Form 20-F Information 2025 and the Interim Financial Statements for the six months ended 30 June 2026 (the Disclosures). Information about the nature and facts of the cases is disclosed in accordance with IAS 37 ‘Provisions, Contingent Liabilities and Contingent Assets’. As discussed in the Disclosures, the majority of claims involve highly complex issues. Often these issues are subject to substantial uncertainties and, therefore, the probability of a loss, if any, being sustained and/or an estimate of the amount of any loss is difficult to ascertain. In cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed and which are not subject to appeal, or where a loss is probable and we are able to make a reasonable estimate of the loss, AstraZeneca records the loss absorbed or makes a provision for its best estimate of the expected loss. The position could change over time and the estimates that the Company made, and upon which the Company have relied in calculating these provisions are inherently imprecise. There can, therefore, be no assurance that any losses that result from the outcome of any legal proceedings will not exceed the amount of the provisions that have been booked in the accounts. The major factors causing this uncertainty are described more fully in the Disclosures and herein. AstraZeneca has full confidence in, and will vigorously defend and enforce, its IP.
Page 33
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 33 Matters disclosed in respect of the third quarter of 2026 and up to and including 29 October 2026 Patent litigation Legal proceedings brought by AstraZeneca Farxiga patent proceedings, US In May 2021, AstraZeneca proceeded to trial against ANDA filer Zydus Pharmaceuticals (USA) Inc. (Zydus) in the US District Court for the District of Delaware (District Court). In October 2021, the District Court issued a decision finding the asserted claims of AstraZeneca’s patent as valid and infringed by Zydus’s ANDA product. In August 2022, Zydus appealed the District Court decision. Zydus’s appeal has been dismissed. In December 2023, AstraZeneca initiated ANDA litigation against Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc. in the District Court. In September 2026, the District Court dismissed the matter. This matter is concluded. Koselugo patent proceedings, US In September 2026, AstraZeneca received a paragraph IV notice from Hetero USA, Inc. challenging patents relating to Koselugo. AstraZeneca intends to file responsive ANDA litigation. This matter remains at an early stage. Lynparza patent proceedings, Canada In July 2025, AstraZeneca was served with a Notice of Allegation from Cipla Ltd (Cipla) challenging a patent relating to Lynparza. AstraZeneca commenced an action in response in August 2025. In August 2026, AstraZeneca entered into a settlement agreement with Cipla resolving all Canada patent litigation with Cipla relating to Lynparza. In August 2025, AstraZeneca was served with a Notice of Allegation from Natco Pharma (Canada) Inc. (Natco) challenging a patent relating to Lynparza. AstraZeneca commenced an action in response in October 2025. In September 2026, AstraZeneca entered into a settlement agreement with Natco resolving all Canada patent litigation with Natco relating to Lynparza. In November 2025, AstraZeneca was served with a Notice of Allegation from Zydus Lifesciences Limited challenging a patent relating to Lynparza. AstraZeneca commenced an action in response in December 2025. A summary trial related to infringement is scheduled for January 2027 and a trial on other matters has not yet been scheduled. Lynparza patent proceedings, US AstraZeneca received a Paragraph IV notice relating to Lynparza patents from Natco Pharma Limited (Natco) in December 2022, Sandoz Inc. (Sandoz) in December 2023, Cipla USA, Inc. and Cipla Limited (collectively, Cipla) in May 2024, and Zydus Pharmaceuticals (USA) Inc. (Zydus) in November 2024. In response to these Paragraph IV notices, AstraZeneca, MSD International Business GmbH, and the University of Sheffield initiated ANDA litigations against Natco, Sandoz, Cipla, and Zydus in the US District Court for the District of New Jersey. In the complaints, AstraZeneca alleged that the defendants’ generic versions of Lynparza, if approved and marketed, would infringe AstraZeneca’s patents. In April 2026, AstraZeneca entered into a settlement agreement with Sandoz resolving all US patent litigation with Sandoz relating to Lynparza. Trial has been scheduled to commence with the remaining defendants in January 2027. In June 2026, AstraZeneca received Paragraph IV notices from Cipla relating to Lynparza dosage strengths not at issue in the previous litigation. In July 2026, AstraZeneca commenced responsive litigation. That matter remains at an early stage.
Page 34
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 34 Tagrisso patent proceedings, Russia In August 2023, AstraZeneca filed lawsuits in the Arbitration Court of the Moscow region (Court) against the Russian Ministry of Health (MOH) and Axelpharm LLC (Axelpharm) for improper use of AstraZeneca information in the authorisation of a generic version of Tagrisso. The suit against the MOH was dismissed in July 2024, after two appeals. The case against Axelpharm was dismissed in September 2024, and a subsequent appeal by AstraZeneca was also dismissed. In November 2023, Axelpharm sought a compulsory licence under a patent related to Tagrisso; the action remains pending. The Axelpharm patent on which the compulsory licensing action was based was held invalid by the Russian Patent and Trademark Office (PTO) in August 2024, following a challenge by AstraZeneca. The PTO’s decision was upheld in June 2025, following an appeal by Axelpharm. At a further appeal hearing in November 2025, the Intellectual Property Court Presidium reversed earlier decisions and held Axelpharm’s patent valid. The Supreme Court rejected appeals by AstraZeneca and the PTO against this decision in February 2026. AstraZeneca filed a new invalidity claim against Axelpharm’s patent in May 2026. In July 2024, AstraZeneca filed a patent infringement claim against Axelpharm in relation to a generic version of Tagrisso. The action was stayed by the Court pending resolution of the compulsory licensing action. In July 2026, AstraZeneca filed a patent infringement claim against OncoTarget LLC (OncoTarget) in relation to the manufacture of a generic version of Tagrisso and a further claim against Pharmproekt Limited Liability Company based on their participation in tenders relating to a generic version of Tagrisso. In August 2024, after AstraZeneca filed a complaint, the Federal Anti-Monopoly Service of Russia (FAS) initiated a case against Axelpharm and OncoTarget. In November 2024, the FAS found Axelpharm (but not OncoTarget) to have committed unfair competition. In June 2025, the finding against Axelpharm was reversed on appeal. In December 2025, on appeal by AstraZeneca, the appellate decision was affirmed. AstraZeneca filed a further appeal, and in April 2026, the Intellectual Property Court restored the FAS’s finding of unfair competition and prohibited Axelpharm from selling the generic drug. Commercial litigation Legal proceedings brought against AstraZeneca Farxiga Privacy Litigation, US Considered to be a contingent liability In September 2026, a putative class action was filed in California State Court alleging that tracking technologies used on the Farxiga website collected and disclosed certain visitor information in violation of the privacy laws of California and other states. This matter remains at an early stage. Syntimmune Milestone Litigation, US Considered to be a contingent liability As previously disclosed, since 2020, AstraZeneca has been defending a lawsuit filed in connection with AstraZeneca's acquisition of Syntimmune, Inc. (Syntimmune) by the stockholders’ representative for Syntimmune in Delaware State Court (Court) that alleged, among other things, breaches of the 2018 merger agreement (Merger Agreement). The stockholders’ representative alleged that AstraZeneca failed to meet its obligations under the Merger Agreement to use commercially reasonable efforts to achieve the milestones. AstraZeneca also filed a claim for breach of the representations in the Merger Agreement. A trial was held in July 2023. The Court issued partial decisions in September 2024, June 2025, and May 2026, concluding that the first milestone was achieved, that AstraZeneca had breached its contractual obligation to use commercially reasonable efforts to achieve the milestones, and that sellers breached a material representation in the Merger Agreement regarding manufacturing of drug substance and product supply. In October 2026, the Court entered final judgment on its earlier decisions issuing a $392 million judgment, plus post judgment interest, against AstraZeneca. AstraZeneca intends to appeal.
Page 35
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 35 Government investigations and proceedings Legal proceedings brought against AstraZeneca Respiratory Biologics False Claims Act Litigation, US Considered to be a contingent liability In October 2026, AstraZeneca was served with an unsealed civil lawsuit brought by qui tam relators on behalf of the federal government and several states, which alleges that AstraZeneca engaged in unlawful marketing practices in connection with its promotion of Fasenra and Tezspire. Several other manufacturers are also named in the complaint with respect to their promotion of other respiratory biologics. This matter remains at an early stage. Legal proceedings brought by AstraZeneca 340B State Litigation, US Considered to be a contingent asset AstraZeneca has ongoing lawsuits against Arkansas, Colorado, Hawaii, Louisiana, Maine, Maryland, Mississippi, Missouri, Nebraska, New Mexico, North Dakota, Oklahoma, Oregon, Rhode Island, South Dakota, Tennessee, Utah, Vermont, Washington, and West Virginia challenging the constitutionality of each state’s 340B statute. AstraZeneca has ongoing enforcement actions in Arkansas and Louisiana for alleged non- compliance with each state's 340B statute. In July 2026, Louisiana issued a cease-and-desist letter concerning AstraZeneca's 340B policy. In August and September 2026, the Mississippi and Arkansas District Courts, respectively, granted summary judgment in favor of those states. AstraZeneca has appealed or intends to appeal those decisions. In August 2026, courts in Colorado, Maine, and South Dakota dismissed AstraZeneca’s complaints. AstraZeneca has appealed. In August 2026, AstraZeneca was served with an unfair trade practices complaint by the State of Arkansas concerning its 340B policies. Calquence Inflation Reduction Act Litigation, US Considered to be a contingent asset In December 2025, AstraZeneca filed a lawsuit in the US District Court for the District of Maryland (District Court) challenging the Center for Medicare and Medicaid Studies' interpretation of “qualifying single source drug” under the Inflation Reduction Act and its application in selecting Calquence for drug price negotiation. In August 2026, the District Court entered judgment against AstraZeneca and AstraZeneca appealed. Tagrisso Regulatory Proceedings, UK and Europe In May 2026, AstraZeneca filed separate legal actions in the UK High Court and the General Court of the European Union challenging determinations by the Medicines and Healthcare products Regulatory Agency and the European Medicines Agency to grant marketing authorizations for Hansoh’s aumolertinib. No trial date has been set. In September 2026, the European Commission revoked the marketing authorization for aumolertinib. Other Additional government inquiries As is true for most, if not all, major prescription pharmaceutical companies, AstraZeneca is currently involved in multiple inquiries into drug marketing and pricing practices. In addition to the investigations described above, various law enforcement offices have, from time to time, requested information from the Group. There have been no material developments in those matters. Note 7: Subsequent events On 5 October 2026, AstraZeneca completed its $2.0 billion equity investment in Summit Therapeutics Inc., with the full amount paid at closing. The investment gives AstraZeneca rights equivalent to approximately 12.0% of Summit Therapeutics outstanding common stock, or approximately 10.6% on a fully diluted basis, and has been recognised as a non-current investment in Q4 2026.
Page 36
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 36 Note 8: Analysis of Revenue and Other operating income and expense Table 23: Product Sales year-on-year analysis: 9M 2026 For the nine months World US Emerging Markets Europe Established RoW ended 30 September Change Change Change Change Change $m Act % CER % $m Act % $m Act % CER % $m Act % CER % $m Act % CER % Tagrisso 5,862 10 8 2,467 11 1,656 10 6 1,169 13 8 570 (3) 1 Imfinzi 5,538 28 27 3,128 26 627 35 33 1,210 38 31 573 17 23 Calquence 3,009 18 16 1,982 16 214 31 25 690 21 16 123 6 6 Lynparza 2,421 1 (2) 1,012 (4) 507 4 (1) 710 6 1 192 - 3 Enhertu 1,019 49 45 - - 701 47 44 205 41 33 113 78 75 Zoladex 932 9 5 18 35 745 13 8 119 6 1 50 (24) (26) Truqap 641 30 29 450 9 55 n/m n/m 97 n/m n/m 39 82 87 Imjudo 263 4 4 157 (5) 33 89 86 43 21 16 30 (14) (10) Datroway 12 n/m n/m - - 11 n/m n/m 1 n/m n/m - - - Etcamah 10 n/m n/m 7 n/m 3 n/m n/m - - - - - - Other Oncology 311 (3) (4) 7 20 215 - (3) 12 (20) (21) 77 (11) (5) Oncology 20,018 16 14 9,228 14 4,767 19 15 4,256 22 16 1,767 6 10 Farxiga 5,602 (12) (15) 795 (36) 2,200 (16) (21) 2,385 11 6 222 (32) (30) Crestor 1,017 8 5 27 (25) 912 13 9 1 28 (14) 77 (19) (16) Lokelma 638 23 23 239 6 149 50 44 136 50 44 114 13 20 Seloken 518 11 6 - n/m 500 11 6 15 6 3 3 6 (4) Brilinta 261 (61) (62) 16 (95) 207 2 (1) 33 (75) (76) 5 (33) (36) Wainua 189 33 33 170 24 5 39 47 12 n/m n/m 2 n/m n/m roxadustat 78 (66) (67) - - 78 (66) (67) - - - - - - Baxfendy 12 n/m n/m 11 n/m 1 n/m n/m - - - - - - Other CVRM 298 (29) (30) (11) n/m 212 2 - 55 (54) (55) 42 (11) (6) CVRM 8,613 (11) (15) 1,247 (38) 4,264 (8) (12) 2,637 5 - 465 (20) (17) Symbicort 2,084 (4) (7) 772 (15) 653 5 1 425 5 (1) 234 (5) (7) Fasenra 1,655 14 13 949 7 149 85 78 389 11 5 168 26 30 Breztri 1,073 18 16 479 4 329 38 31 183 34 28 82 19 21 Tezspire 509 61 57 - - 64 n/m n/m 322 56 49 123 43 48 Saphnelo 615 27 27 516 23 18 72 72 57 68 61 24 36 41 Pulmicort 378 6 2 5 43 309 10 6 42 (9) (14) 22 (19) (19) Airsupra 129 12 13 120 6 9 n/m n/m - - - - - - Other R&I 182 (14) (16) 22 (67) 79 (17) (20) 76 74 68 5 (6) (6) R&I 6,625 10 8 2,863 - 1,610 19 14 1,494 22 16 658 12 14 Beyfortus 147 (34) (34) 84 (39) - - - 61 (26) (27) 2 (17) (29) FluMist 172 30 29 19 (3) 7 n/m n/m 102 24 24 44 52 49 Other ID 136 (38) (41) (1) (38) 106 (34) (38) 21 (43) (48) 10 (60) (57) ID* 455 (21) (22) 102 (34) 113 (30) (34) 184 (9) (10) 56 (1) (2) Ultomiris 4,016 16 16 2,190 12 306 73 73 915 19 14 605 11 16 Soliris 1,076 (25) (26) 595 (30) 311 (5) (7) 89 (44) (47) 81 (24) (23) Strensiq 1,641 38 37 1,332 40 111 81 67 104 17 12 94 11 17 Koselugo 585 17 15 149 (5) 225 20 17 149 29 23 62 63 72 Other Rare Disease 226 28 25 89 7 51 39 25 60 20 14 26 n/m n/m Rare Disease 7,544 12 11 4,355 9 1,004 27 24 1,317 11 6 868 11 16 Other Medicines 707 (5) (6) 56 14 531 (6) (8) 60 3 - 60 (14) (12) Total Medicines 43,962 7 5 17,851 4 12,289 7 3 9,948 15 9 3,874 4 7 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. * ID: Infectious Disease
Page 37
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 37 Table 24: Product Sales year-on-year analysis: Q3 2026 For the quarter World US Emerging Markets Europe Established RoW ended 30 September Change Change Change Change Change $m Act % CER % $m Act % $m Act % CER % $m Act % CER % $m Act % CER % Tagrisso 2,087 12 12 888 13 608 21 18 400 7 8 191 (8) (1) Imfinzi 1,990 24 26 1,120 23 229 36 35 429 25 27 212 19 29 Calquence 1,065 16 16 696 14 77 26 24 248 24 25 44 2 4 Lynparza 811 (3) (3) 353 (3) 164 - (2) 230 (5) (4) 64 (3) 3 Enhertu 357 39 37 - - 261 42 40 73 40 41 23 8 4 Zoladex 325 14 10 9 n/m 265 21 16 38 (5) (5) 13 (41) (42) Truqap 210 9 9 144 (10) 20 n/m n/m 32 83 85 14 56 66 Imjudo 103 23 25 57 4 20 n/m n/m 15 17 21 11 5 11 Datroway 7 n/m n/m - n/m 6 n/m n/m 1 n/m n/m - - - Etcamah 7 n/m n/m 7 n/m - - - - - - - - - Other Oncology 108 2 3 3 64 74 7 5 4 (17) (3) 27 (10) - Oncology 7,070 15 15 3,277 13 1,724 25 22 1,470 15 16 599 2 9 Farxiga 1,605 (25) (25) 127 (71) 582 (35) (37) 799 14 16 97 (5) 1 Crestor 332 9 6 9 (25) 300 15 11 - n/m n/m 23 (27) (23) Lokelma 219 16 17 75 (8) 56 55 50 49 41 43 39 8 15 Seloken 181 13 9 - n/m 174 14 9 6 3 2 1 6 3 Brilinta 75 (48) (50) - n/m 65 (1) (5) 9 (61) (60) 1 (51) (45) Wainua 68 16 17 61 11 1 (63) (32) 5 n/m n/m 1 n/m n/m roxadustat 21 (73) (74) - - 21 (73) (74) - - - - - - Baxfendy 9 n/m n/m 9 n/m - - - - - - - - - Other CVRM 92 (36) (34) (2) n/m 67 (3) (4) 13 (70) (68) 14 (4) 5 CVRM 2,602 (19) (20) 279 (58) 1,266 (19) (21) 881 9 11 176 (6) - Symbicort 666 (10) (11) 227 (26) 236 5 2 129 (4) (4) 74 (6) (5) Fasenra 602 13 14 355 8 57 n/m 95 131 7 8 59 18 25 Breztri 374 16 14 170 2 121 45 37 56 15 17 27 12 16 Tezspire 188 58 61 - - 20 n/m n/m 120 53 53 48 51 58 Saphnelo 235 31 32 198 27 7 94 88 21 60 66 9 29 38 Pulmicort 109 18 16 2 n/m 90 25 23 11 (9) (10) 6 (32) (22) Airsupra 42 (7) (4) 42 (3) - n/m n/m - - - - - - Other R&I 52 (3) (3) 7 (43) 24 (2) (4) 19 28 28 2 11 (12) R&I 2,268 9 9 1,001 (1) 555 25 21 487 15 15 225 11 16 Beyfortus 76 (19) (20) 23 (34) - - - 52 (12) (12) 1 - - FluMist 146 20 20 21 7 6 n/m n/m 102 24 24 17 (11) (7) Other ID 44 (24) (25) - n/m 36 (8) (12) 5 (54) (52) 3 (65) (55) ID* 266 (3) (3) 44 (19) 42 5 1 159 5 5 21 (24) (22) Ultomiris 1,432 17 19 792 15 116 82 86 310 14 16 214 7 15 Soliris 298 (35) (35) 181 (34) 63 (38) (37) 28 (40) (42) 26 (29) (27) Strensiq 588 33 34 473 28 46 n/m n/m 36 13 15 33 12 23 Koselugo 238 6 9 55 7 110 (2) - 50 13 15 23 47 59 Other Rare Disease 77 20 24 31 7 17 2 (1) 19 18 22 10 n/m n/m Rare Disease 2,633 9 10 1,532 8 352 15 17 443 8 9 306 8 16 Other Medicines 227 (2) (3) 14 48 172 - (1) 21 (9) (13) 20 (30) (24) Total Medicines 15,066 5 5 6,147 2 4,111 5 3 3,461 12 13 1,347 2 9 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. * ID: Infectious Disease
Page 38
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 38 Table 25: Alliance Revenue: 9M 2026 For the nine months ended 30 September 2026 $m 2025 $m Enhertu 1,670 1,291 Tezspire 614 453 Beyfortus 279 252 Datroway 164 38 Other royalty revenue 76 70 Other Alliance Revenue 3 4 Total 2,806 2,108 Table 26: Collaboration Revenue: 9M 2026 For the nine months ended 30 September 2026 $m 2025 $m Farxiga: sales milestones 80 81 Crestor: sales milestones 32 - Other Collaboration Revenue 1 12 Total 113 93 Table 27: Other operating income and expense: 9M 2026 For the nine months ended 30 September 2026 $m 2025 $m Disposal of Zoryve interest 100 - Other 518 281 Total 618 281
Page 39
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 39 Financial calendar – Announcement of FY and Q4 2026 results: 9 February 2027 Dividend payment dates Dividends are normally paid as follows: – First interim: Announced with the half-year results and paid in September – Second interim: Announced with the full-year results and paid in March Contact details For Investor Relations contacts, click here. For Media contacts, click here. Addresses for correspondence Registered office UK Registrar and Transfer Office Swedish Central Securities Depository US Registrar and Transfer Agent 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA Computershare Investor Services PLC The Pavilions Bridgwater Road Bristol BS99 6ZZ Euroclear Sweden AB PO Box 191 SE-101 23 Stockholm Computershare Investor Services PO Box 43078 Providence RI, 02940-3078 UK UK Sweden US +44 (0) 20 3749 5000 0800 707 1682 (UK only) +46 (0) 8 402 9000 +1 (888) 697 8018 (US only) +44 (0) 370 707 1682 +1 (781) 575 2844 Trademarks Trademarks of the AstraZeneca group of companies appear throughout this document in italics. Medical publications also appear throughout the document in italics. AstraZeneca, the AstraZeneca logotype and the AstraZeneca symbol are all trademarks of the AstraZeneca group of companies. Trademarks of companies other than AstraZeneca that appear in this document include: Beyfortus, a trademark of Sanofi Pasteur Inc.; Enhertu and Datroway, trademarks of Daiichi Sankyo; Seloken, owned by AstraZeneca or Taiyo Pharma Co., Ltd (depending on geography); Synagis, owned by AstraZeneca or Sobi aka Swedish Orphan Biovitrum AB (publ) (depending on geography); Tezspire, a trademark of Amgen, Inc; and Zoryve a trademark of Arcutis Biotherapeutics, Inc. Information on or accessible through AstraZeneca's websites, including astrazeneca.com, does not form part of and is not incorporated into this announcement. Other shareholder information
Page 40
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 40 AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca. Cautionary statements regarding forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: – the risk of failure or delay in delivery of the pipeline or launch of new medicines – the risk of failure to meet regulatory or ethical requirements for medicine development or approval – the risk of failures or delays in the quality or execution of the Group’s commercial strategies – the risk of pricing, affordability, access and competitive pressures – the risk of failure to maintain supply of compliant, quality medicines – the risk of illegal trade in the Group’s medicines – the risk of reliance on third-party goods and services – the risk of failure in IT or cybersecurity – the risk of failure of critical processes – the risk of failure to collect and manage data and AI in line with legal and regulatory requirements and strategic objectives – the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce – the risk of failure to meet sustainability targets, regulatory requirements or stakeholder expectations with respect to the environment – the risk of failure to meet regulatory and ethical expectations on commercial practices, including anti-bribery/anti-corruption, anti- fraud and scientific exchanges – the risk of the safety and efficacy of marketed medicines being questioned – the risk of adverse outcome of litigation and/or governmental investigations – intellectual property-related risks to the Group’s products – the risk of failure to achieve strategic plans or meet targets or expectations – the risk of geopolitical and/or macroeconomic volatility disrupting the operation of the Group’s global business – the risk of failure in internal control, financial reporting or the occurrence of fraud – the risk of unexpected deterioration in the Group’s financial position.
Page 41
Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 41 1L, 2L, etc First line, second line, etc 6MWT Six-minute walk test ADC Antibody drug conjugate aHUS Atypical haemolytic uraemic syndrome AI Aromatase inhibitors AL Amyloid light chain ANDA Abbreviated New Drug Application (US) ASBMR American Society for Bone and Mineral Research ATTR / -CM / -PN Transthyretin-mediated amyloid / cardiomyopathy / polyneuropathy BC Breast cancer BCG Bacillus Calmette-Guérin therapy BPI-SF Brief Pain Inventory - Short Form BRCA / m / wt Breast cancer gene / mutation / wild-type BTK Bruton tyrosine kinase CDK4, CDK6 Cyclin-dependent kinase 4 / 6 CER Constant exchange rates CHMP Committee for Medicinal Products for Human Use (EU) CI Confidence interval CLDN-18 Claudin-18 CLL Chronic lymphocytic leukaemia CN China COPD Chronic obstructive pulmonary disease CRSwNP Chronic rhinosinusitis with nasal polyps CV Cardiovascular CVRM Cardiovascular, Renal and Metabolism DSQ Dysphagia Symptom Questionnaire EBITDA Reported Profit before tax after adding back Net finance expense, results from joint ventures and associates, and charges for Depreciation, amortisation and impairment EFS Event-free survival EGFR / m Epidermal growth factor receptor gene / mutation EGPA Eosinophilic granulomatosis with polyangiitis EPS Earnings per share ER Oestrogen receptor ERS European Respiratory Society ESC European Society of Cardiology ESMO European Society for Medical Oncology ESR1 / m Oestrogen Receptor 1 gene / mutation ES-SCLC Extensive stage small cell lung cancer EU Europe (in financial tables) or European Union EVH Extravascular haemolysis FDA US Food and Drug Administration FDC Fixed dose combination FY Full year / Financial year GAAP Generally Accepted Accounting Principles GAAP Generally Accepted Accounting Principles GEJ Gastro oesophageal junction GI Gastrointestinal gMG Generalised myasthenia gravis GU Genito-urinary GYN Gynaecological HER2 / +/- /low /m Human epidermal growth factor receptor 2 gene / positive / negative / low expression / mutant HES Hypereosinophilic syndrome HPP Hypophosphatasia HR / + / - Hormone receptor / positive / negative HRD Homologous recombination deficiency HSCT-TMA Hematopoietic stem cell transplantation- associated thrombotic microangiopathy HSPC Hormone-sensitive prostate cancer IAS / B International Accounting Standards / Board IASLC International Association for the Study of Lung Cancer ICS Inhaled corticosteroid ID Infectious Disease IDMC Independent Data Monitoring Committee IFRS International Financial Reporting Standards IgAN Immunoglobulin A nephropathy IHC Immunohistochemistry IL-5, IL-33, etc Interleukin-5, interleukin-33, etc JP Japan LABA Long-acting beta-2 agonist LAMA Long-acting muscarinic-antagonist LOE Loss of exclusivity m Metastatic (e.g. mBTC , mCRPC) MASH Metabolic dysfunction-associated steatohepatitis MCL Mantle cell lymphoma MET Mesenchymal-epithelial transition MIBC Muscle-invasive bladder cancer n/m Growth rate not meaningful NGP Next-generation propellant NME New molecular entity NMIBC Non muscle-invasive bladder cancer NMOSD Neuromyelitis optica spectrum disorder NRDL National reimbursement drug list NSCLC Non-small cell lung cancer o Oral (e.g. oGLP1, oPCSK9) OS Overall survival PARP / i / -1sel Poly ADP ribose polymerase / inhibitor / -1 selective PD-1 Programmed cell death protein 1 PD-L1 Programmed death-ligand 1 PFS Progression-free survival PNH Paroxysmal nocturnal haemoglobinuria PR Partial response PTEN Phosphatase and tensin homologue gene R&I Respiratory & Immunology RR Relative reduction SEC Securities Exchange Commission (US) SG&A Sales, general and administration TKI Tyrosine kinase inhibitor TNBC Triple negative breast cancer UEGW United European Gastroenterology Week VBP Volume-based procurement VEGF Vascular endothelial growth factor WCLC World Conference on Lung Cancer Glossary